david h. bernstein (dhbernstein@debevoise.com) michael...
Post on 10-Apr-2018
218 Views
Preview:
TRANSCRIPT
David H. Bernstein (dhbernstein@debevoise.com)Michael Schaper (mschaper@debevoise.com)Christopher J. Hamilton (cjhamilton@debevoise.com)DEBEVOISE & PLIMPTON LLP919 Third AvenueNew York, New York 10022(212) 909-6696 (telephone)(212) 521-7696 (facsimile)
Attorneys for Plaintiff Bayer HealthCare LLC
UNITED STATES DISTRICT COURTSOUTHERN DISTRICT OF NEW YORK- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - XBAYER HEALTHCARE LLC,
Plaintiff,
v.
ELI LILLY AND COMPANY,
Defendant.
::::::::::
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X
11 Civ. 3047 (AKH)ECF CASE
COMPLAINT AND DEMAND FOR JURY TRIAL
Bayer HealthCare LLC (“Bayer”), by its attorneys, Debevoise & Plimpton LLP,
for its complaint, alleges as follows:
NATURE OF THE ACTION
1. This is an action for false advertising and unfair competition, under federal
and state law against Eli Lilly and Company, whose Elanco division competes directly
against Bayer’s Animal Health Division in the sale of pet medicines. Rather than
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 1 of 38
2
compete fairly, Elanco is engaged in an unfair and deceptive campaign to convince
distribution agents and veterinarians to terminate business relations with Bayer.
2. Specifically, Elanco has embarked on an unlawful campaign to convince
distribution agents and veterinarians to stop selling Bayer’s products, ostensibly because
Bayer’s sale of pet medicines through retail stores is responsible for a decline in profits
for veterinarians. That is maliciously false. Elanco also deceptively claims to
distribution agents and veterinarians that its pet medicines are sold to pet owners only
through veterinarians, despite the fact that Elanco’s products are widely available to the
public through non-veterinarian Internet websites.
3. Elanco’s unlawful conduct is causing and will continue to cause harm to
Bayer. On information and belief, Bayer has lost sales and relationships with distribution
agents and veterinarians as a result of Elanco’s campaign of deception. This conduct, if
not enjoined, will cause irreparable harm to Bayer’s business relationships with
distribution agents and veterinarians.
THE PARTIES
4. Bayer HealthCare LLC is a limited liability company organized and existing
under the laws of the State of Delaware with its principal place of business at 511
Benedict Avenue, Tarrytown, New York 10591. Bayer owns rights in the United States
to a number of pet medicine brands, including flea and tick preventatives such as
Advantage® II and K9 Advantix® II. These brands are distributed in New York,
throughout the United States, and in many international markets.
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 2 of 38
3
5. Upon information and belief, Elanco is an unincorporated division of Eli Lilly
and Company, with its principal place of business at 2001 West Main Street, Greenfield,
Indiana 46140. Eli Lilly and Company is a corporation organized and existing under the
laws of the State of Indiana with its principal place of business at Lilly Corporate Center,
Indianapolis, Indiana 46285. Upon information and belief, Elanco produces pet
medicines including flea and tick preventatives such as Comfortis, Assurity and Trifexis,
and sells its products throughout the United States, including in this District.
JURISDICTION AND VENUE
6. This Court has original jurisdiction over the subject matter of this action
pursuant to 15 U.S.C. § 1121 and 28 U.S.C. §§ 1331, 1332 and 1338 and has
supplemental jurisdiction pursuant to 28 U.S.C. § 1367. The amount in controversy is in
excess of $75,000, exclusive of interest and costs.
7. This Court has personal jurisdiction over Elanco pursuant to N.Y. Civ. Prac.
L. & R. §§ 301 & 302(a). Upon information and belief, Elanco regularly has solicited
business in the State of New York and in this District, has transacted and done business
in the State of New York and in this District, has wrongfully caused injury to Bayer in the
State of New York and in this District, such injury being reasonably foreseeable, and
derives substantial revenue from interstate commerce.
8. On information and belief, venue is proper in this District pursuant to 28
U.S.C. § 1391(b) because a substantial part of the events giving rise to this action
occurred in this District, including the distribution of the false advertising to veterinarians
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 3 of 38
4
in this District. Venue also is proper in this District pursuant to 28 U.S.C. § 1391(c)
because Elanco is deemed to reside in this District.
THE PET MEDICINE MARKET
9. Bayer and Elanco are direct competitors in the market for pet medicines. Both
companies manufacture, among other products, flea and tick preventatives for cats and
dogs.
10. Bayer manufactures the flea and tick preventatives Advantage® II and K9
Advantix® II. Bayer is the second largest manufacturer of flea and tick preventatives in
the United States. Bayer also manufactures other pet medicines, such as the heartworm
preventative Advantage Multi®. Bayer has sold pet medicines since 1921.
11. Elanco has manufactured medicine products for food animals, such as cattle,
swine and poultry, since 1954. Elanco entered the market for pet medicine more
recently, in 2007. In that year, Elanco launched its first flea preventative, Comfortis. In
2011, Elanco introduced two additional flea and tick preventatives, Assurity and Trifexis.
Elanco also makes the Reconcile product, for treatment of canine separation anxiety.
12. With its entry into the field, Elanco joined a crowded field of competitors,
including Novartis, Merial, Pfizer, Merck, Hartz and Farnam. Bayer welcomes such
competition, but that competition should be fair and legal. As explained below, Elanco
has used tactics that are unfair and illegal.
13. In the United States, manufacturers sell pet medicines primarily through two
distinct distribution systems. First, manufacturers sell pet medicines to retail stores,
including pet stores (e.g., Petco, Petsmart) and pharmacies. Second, manufacturers sell
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 4 of 38
5
pet medicines to veterinarians, including pet hospitals and veterinary clinics. For the
most part, these veterinarians sell the pet medicines directly to pet owners. In both cases,
some sales are made directly from the manufacturer to the retailers and veterinarians, and
others are made through distributors or distribution agents. In most cases, the distributors
through which products are sold to the retail trade are distinct from the distribution agents
through which products are sold to veterinarians.
14. Some pet medicines are subject to Food and Drug Administration (the
“FDA”) regulations, and thus are available only by prescription. These prescription
products can be purchased by pet owners only from veterinarians and pharmacies.
Manufacturers cannot legally sell prescription pet medicines to retail stores or websites
other than pharmacies. Examples of such prescription pet medicines include Bayer’s
Advantage Multi® product and Elanco’s Comfortis, Trifexis and Reconcile products.
15. Other pet medicines (including topical applications not regulated by the FDA)
can legally be sold through pet stores and general retail outlets. Examples of such non-
prescription pet medicines include Bayer’s Advantage® II and K9 Advantix® II products,
and Elanco’s Assurity product.
16. Until March 2010, both Bayer and Elanco sold their entire lines of pet
medicines exclusively to veterinarians.
17. Although Bayer and Elanco did not sell their pet medicines to retail stores or
Internet pharmacies during that period, a number of these products nevertheless could be
purchased in retail stores or via the Internet because some veterinarians resold – or
“diverted” – pet medicines to retail stores or Internet pharmacies in large quantities at a
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 5 of 38
6
considerable profit. Although veterinarians’ diversion of pet medicines from the
veterinary market to this non-veterinary market violated the terms of Bayer’s and
Elanco’s sales policies, this practice was and is common in the sale of many pet
medicines. For example, Merial also only sells its Frontline products to veterinarians, but
its products also are diverted and widely available at retail stores and the Internet.
18. Bayer recognized that the small number of veterinarians who were diverting
products to the retail market were profiting at the expense both of Bayer and of honest
veterinarians. In March 2010, after a lengthy business evaluation, Bayer announced its
decision to begin selling directly to the pet specialty market (i.e., those retailers where at
least fifty percent of sales are products, services and goods for pets) through purchase
agreements and through authorized distributors for this retail channel. These direct sales
are leading to a replacement of diversion from the veterinary channel to this retail
channel.
19. Even after March 2010, Bayer has continued to sell its pet medicines to
veterinarians; in fact, the majority of its flea and tick preventatives and other products
still remain in the veterinary channel. To support veterinarians’ sales of Advantage® II
and K9 Advantix® II, Bayer offers promotions that encourage consumers to take their
pets to see their veterinarian. For example, Bayer coupon offers, whether made available
through direct mail, email, Internet, or veterinary clinics, are valid for use only on
products purchased at the veterinary clinic. In addition, Bayer provides veterinarians
with promotional materials – for example, product displays, “shelf talkers,” window
clings, and posters – for display in their offices. Bayer also educates consumers about the
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 6 of 38
7
importance of taking their pets to the vet. All Bayer television advertising – including the
current K9 Advantix® II commercial and an unbranded public service announcement
regarding canine heartworm prevention – include a call to action for viewers to talk to or
see their veterinarian. In 2010, Bayer spent $2 million on a print advertisement that
stressed the importance of visiting veterinarians and getting wellness checks for pets,
building on the 2009 “Get Your Pet to the Vet” nationwide sweepstakes campaign which
provided $20 vouchers for pet owners for use on veterinary care.
20. Bayer has also continued to support the veterinary market and practice in
other ways. For example, Bayer commissioned a study of veterinary care usage
published in the May 15, 2011 issue of the Journal of the American Veterinary Medical
Association that suggested ways in which veterinarians can increase the frequency of
patient visits. See Ex. A. Further, Bayer contributes to veterinary education, including
through scientific research, the production of online seminars on a variety of topics, the
provision of continuing veterinary medical educational credits and the endowment of
educational grants to a number of universities and veterinary schools. Bayer also
supports veterinary associations and organizations – for example, the American
Veterinary Medical Association and state and local veterinary medical associations, the
Companion Animal Parasite Council, and the American Heartworm Society – through
sponsorships and involvement on their boards.
ELANCO’S FALSE AND MISLEADING STATEMENTS TO VETERINARIANS
21. On or before April 18, 2001, Elanco distributed a “Dear Doctor” letter to a
large number of veterinarians nationwide, including in New York and in this District (the
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 7 of 38
8
“Letter,” attached as Ex. B). The Letter contained a series of false and misleading
statements which falsely and maliciously portrayed Bayer as undermining the business
interests of veterinarians and as being solely responsible for a decline in sales of flea
preventatives by veterinarians.
22. The Letter stated:
In the past year, Bayer began selling Advantage® and K9
Advantix® products directly to pet retailers and websites.
There appears to be a direct correlation between the decline
in veterinary-dispensed flea medication and the availability
of these products outside the veterinary channel. Sales at
Bayer Animal Health rose by 14.6 percent in 2010.
According to Bayer’s financial statements this came as a
result of strong increases in North America.
23. This statement falsely implies that Bayer’s decision to sell certain products to
pet retailers and websites directly caused a decline in sales of flea preventatives by
veterinarians.
24. In fact, as Elanco undoubtedly is aware, veterinary usage has been in decline
over the past five to ten years, significantly predating Bayer’s decision to sell certain pet
medicines to retail stores. The Bayer-sponsored study of veterinary usage shows that the
major factors contributing to this decline have been the weak economy, the fragmentation
of veterinary services, pet owners’ use of Internet sources to get information about pet
health issues, pet owners’ inadequate understanding of the need for routine examinations,
the cost of veterinary care, and cats’ resistance to be being put in carriers. Ex. A. The
study does not identify the availability of pet medicines in retail stores as a factor in the
decline.
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 8 of 38
9
25. The decline in sales of other pet medicines also demonstrates the falsity of
Elanco’s attempt to blame Bayer for the decline in veterinary sales of flea medicine. For
example, sales of heartworm preventatives by veterinarians declined from 2009 to 2010,
despite the fact that heartworm preventatives are available only by prescription and thus
could not possibly be diverted to non-pharmacy retail stores (which are legally prohibited
from selling such products). Bayer does not sell its heartworm preventative products to
retail stores.
26. The Letter also falsely and maliciously portrayed Bayer as having abandoned
veterinarians to focus on selling to retail stores. The Letter stated:
Not only has Bayer chosen to distribute product outside the
veterinary channel, they have shifted their support for
veterinarians by working directly with large retailers. In
December 2010, a marketing manager for Bayer Animal
Health acknowledged, “Advantage has enjoyed the
recommendation of veterinarians worldwide for the control
of fleas on dogs and cats.” When asked how pet specialty
stores can compete effectively with veterinarians in selling
these products, he responded, “With direct support from
Bayer Animal Health, we can help pet retailers leverage our
expertise in parasite prevention and treatment to get the
message to their customers.”
In fact, (a) Bayer still sells many prescription pet medicines which are not available
through pet stores, (b) the majority of Bayer’s sales of flea and tick preventatives are still
to veterinarians, and (c) as described in paragraphs 19 and 20, Bayer has continued to
support veterinarians with research and promotions.
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 9 of 38
10
27. The statement quoted in paragraph 26 also misrepresents Bayer marketing
manager Daniel Peizer’s statements to Pet Business magazine by taking them out of
context. Mr. Peizer was asked: “How can pet specialty stores effectively compete with
veterinary clinics in selling these products?” His response in its entirety stated:
By building awareness and making flea and tick control an
essential part of pet care for your customers. Visiting the
veterinarian on a regular basis is still the single most
important thing a pet owner can do for the health of their
pet. That said, pet owners visit pet specialty retailers more
frequently than they do their veterinarian on an annual
basis to purchase food and other essential items. While
experts like the Companion Animal Parasite Council
recommend that pet owners apply flea and tick control
year-round in most areas of the country, research shows
that on average pet owners only apply about one-third of
the recommended doses. With direct support from Bayer
Animal Health, we can help pet retailers leverage our
expertise in parasite prevention and treatment to get the
message to their customers.
Ex. C (emphasis added). Mr. Peizer’s full response made clear that pet owners should
visit their veterinarians on a regular basis, and could not reasonably be interpreted as
“shifting support” to retail stores and away from veterinarians. Elanco’s selective
quotations from this interview deliberately create a false and misleading impression.
28. In addition to falsely and maliciously asserting that Bayer is responsible for a
decline in sales by veterinarians of pet medicines, Elanco falsely implied in the Letter
that Elanco ensures that its products are sold only through veterinarians:
Since launching Elanco Companion Animal Health, we
have introduced four products into the marketplace – each
sold exclusively to veterinarians through our veterinary
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 10 of 38
11
distributor partners. To retain the dispensing of these
products within the veterinary channel, Elanco has
implemented Track and Trace technology with our
parasiticide products. Unique identification numbers and
bar coding on boxes and cartons help ensure product
integrity and guard against theft, while helping to keep
these products within the context of the
veterinary/client/patient relationship.
29. This statement falsely implies that Elanco’s products are only available to pet
owners through sales by veterinarians, and that veterinarians need not worry about any
competing sales of Elanco products at retail pharmacies. This is demonstrably not the
case. As Elanco must know, its products are available for purchase through a number of
non-veterinarian Internet pharmacies, including 1800petmeds.com, drsfostersmith.com,
and vetsmall.com. See Ex. D. As evidenced by the detail from vetsmall.com at the top of
the following page, Elanco’s Comfortis product is readily available to Internet
consumers:
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 11 of 38
12
30. Elanco’s statements in the Dear Doctor Letter are literally false and
misleading and were designed by Elanco to cause veterinarians to refrain from
purchasing Bayer pet medicines in a misguided attempt to punish Bayer for allowing
competition at retail stores.
31. In the Letter, Elanco also urged veterinarians to engage in a boycott of Bayer:
Your business is at a crossroad. Will you stand by and
watch while industry “leaders” redirect your patients
outside your office for veterinary products? Will you
endorse companies which disrespect your profession and
redirect patients to other sources? Or will you support
companies whose words are supported by action? At
Elanco, we believe it is critically important to align actions
and words.
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 12 of 38
13
32. On April 19, 2011, Bayer formally requested that Elanco take affirmative
steps to retract and correct the false and misleading statements made in the Letter.
Elanco, however, has refused to correct the problem.
33. This campaign to unfairly interfere with Bayer’s relationship with distributors
and veterinarians is not accidental or new. From 2007 to 2010, Elanco hired twenty-two
former Bayer employees, who had knowledge of Bayer’s business and marketing
strategies, including knowledge of key customers and of Bayer’s relationships with
customers and distribution agents. On information and belief, Elanco has used that
knowledge to disrupt Bayer’s business relationships with distribution agents and
veterinarians by maliciously spreading false statements.
34. On information and belief, during 2010 and 2011, Elanco sales representatives
have also stated to distribution agents and veterinarians during detailer and sales visits
that Bayer’s sale of certain pet medicines to pet retailers and websites has caused a
decline in sales of pet medicine by veterinarians, and have urged distribution agents and
veterinarians to stop purchasing and distributing Bayer’s products and to engage in a
boycott of Bayer.
35. On information and belief, Elanco’s deceptive and unlawful campaign to keep
Bayer from competing in the veterinary market has already caused significant harm to
Bayer’s business, including the loss of sales and of business relationships with
distribution agents and veterinarians. Bayer has lost over a thousand veterinary accounts
during this period of unfair competition by Elanco. These lost accounts had provided
over $16 million in sales in 2010.
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 13 of 38
14
COUNT I: FALSE ADVERTISING
UNDER SECTION 43(a) OF THE LANHAM ACT
36. Bayer repeats and realleges each and every allegation in the foregoing
paragraphs as if fully set forth herein.
37. The false, misleading and deceptive statements set forth above are material
and will tend to deceive distribution agents and veterinarians.
38. Elanco, in connection with goods and services distributed in interstate
commerce, has made and is continuing to make false, deceptive and misleading
descriptions and representations of fact in commercial advertising and promotion, which
misrepresent the nature, characteristics and qualities of Bayer’s and Elanco’s goods,
services and commercial activities, in violation of 15 U.S.C. § 1125(a).
39. These violations have injured and will continue to injure Bayer and the public,
causing deception, confusion and damage in an amount that cannot presently be
ascertained.
40. Elanco’s acts of false advertising and unfair competition have caused
irreparable injury to Bayer and, unless restrained, will cause further irreparable injury,
leaving Bayer with no adequate remedy at law.
41. By reason of the foregoing, Bayer is entitled to permanent injunctive relief
against Elanco restraining further acts of false advertising and unfair competition and
requiring Elanco to correct its false and misleading statements, and to recover damages
caused by reason of Elanco’s aforesaid acts in an amount to be determined at trial.
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 14 of 38
15
COUNT II: FALSE ADVERTISING
UNDER STATE LAW
42. Bayer repeats and realleges each and every allegation in the foregoing
paragraphs as if fully set forth herein.
43. Elanco’s advertising has had an impact on consumers and is deceptive or
misleading in a material way.
44. Bayer has suffered injury as a result of Elanco’s advertising.
45. Elanco’s acts as described above constitute false advertising violations under
N.Y. Gen. Bus. Law § 350 (McKinney 2011) and under analogous laws in other states in
which Elanco’s products and services are sold. See, e.g., Kan. Stat. Ann. § 65-672.
COUNT III: UNFAIR COMPETITION
UNDER STATE COMMON LAW
46. Bayer repeats and realleges each and every allegation in the foregoing
paragraphs as if fully set forth herein.
47. The acts of Elanco as described above constitute unfair competition in
violation of Bayer’s rights under New York State common law and under analogous
unfair competition law in other states in which Elanco has circulated the Letter or made
oral statements as part of its deceptive campaign against Bayer.
PRAYER FOR RELIEF
WHEREFORE, Bayer respectfully prays:
A. That Eli Lilly and Company, Elanco and all those in active
concert or participation with Eli Lilly and Company and Elanco (including, but not
limited to, Eli Lilly and Company’s and Elanco’s officers, directors, agents, servants,
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 15 of 38
16
wholesalers, distributors, retailers, employees, representatives, attorneys, subsidiaries,
related companies, successors, assigns and contracting parties) be permanently enjoined
from distributing, publishing, broadcasting or otherwise disseminating, in any manner or
in any medium, any claims stating, suggesting or implying, directly or indirectly, that:
i. Bayer’s sales of certain pet medicines through retail
stores are responsible for any decline in veterinarians’ profits;
ii. Bayer has shifted its support in the sale of pet
medicines from veterinarians to retail stores; or
iii. Elanco’s pet medicines cannot be purchased by pet
owners from retail stores, such as Internet retailers.
B. That Elanco withdraw and recall from its sales representatives
and any and all channels of distribution any letters, flyers, advertising, promotional
materials, office display materials, or any other matter distributed by it or on its behalf
bearing any descriptions or representations constituting false advertising concerning
Bayer or its products.
C. That Elanco and those in active concert or participation with
Elanco (including, but not limited to, Eli Lilly and Company’s and Elanco’s officers,
directors, agents, servants, wholesalers, distributors, retailers, employees, representatives,
attorneys, subsidiaries, related companies, successors, assigns and contracting parties)
take affirmative steps to dispel such false impressions that heretofore have been created
by the false advertising campaign described above, including, but not limited to,
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 16 of 38
17
notifying all veterinarians, clinics and distribution agents exposed to the false claims
described above that said statements are false.
D. That Eli Lilly and Company account to Bayer for Elanco’s
profits arising from the foregoing acts of false advertising and unfair competition.
E. That, in accordance with such accounting, Bayer be awarded
judgment for such profits and for three times Bayer’s actual damages arising from Eli
Lilly and Company’s and Elanco’s unlawful conduct, pursuant to 15 U.S.C. § 1117, N.Y.
Gen. Bus. Law § 349(h) and analogous state laws, as a result of the willful and
intentional violations of Eli Lilly and Company and Elanco.
F. That Bayer be awarded its costs, including its reasonable
attorneys’ fees and disbursements in this action, pursuant to 15 U.S.C. § 1117, N.Y. Gen.
Bus. Law § 349(h), and analogous state laws.
G. That Bayer be awarded punitive damages pursuant to the law
of the State of New York and the laws of the other states in view of Eli Lilly and
Company’s and Elanco’s malicious acts.
H. That Eli Lilly and Company file with the Court and serve on
counsel for Bayer within thirty (30) days after entry of any injunction issued by the Court
in this action, a sworn written statement pursuant to 15 U.S.C. § 1116(a) setting forth in
detail the manner and form in which Eli Lilly and Company and Elanco have complied
with any injunction which the Court may enter in this action.
I. That Bayer have such other and further relief as the Court may
deem just and proper.
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 17 of 38
18
JURY TRIAL DEMAND
Bayer demands a trial by jury on all claims as to which a jury trial may be had.
Dated: May 4, 2011New York, New York
DEBEVOISE & PLIMPTON LLP
By: /s/ David H. BernsteinDavid H. Bernstein (dhbernstein@debevoise.com)Michael Schaper (mschaper@debevoise.com)Christopher J. Hamilton (cjhamilton@debevoise.com)
919 Third AvenueNew York, New York 10022(212) 909-6696 (telephone)(212) 521-7696 (facsimile)
Attorneys for Plaintiff Bayer HealthCare LLC
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 18 of 38
51>61#">LI"().#"7L%"'&#"6?V"'+#"(&''" >CQ"6CB"<LB?V0";MCAG?I"9CMLOQ" '
8Tal# eXcbegf# [TiX# fhZZXfgXW# g[Tg# g[X# XVbab`\V#eXVXff\ba#bY#/--4#gb#/--6#[TW#T#aXZTg\iX#\`cTVg#
ba#Uhf\aXff#ib_h`X#TaW#eXiXahXf#Ybe#_TeZX#ah`UXef#bY#Vb`cTa\ba# Ta\`T_# iXgXe\aTel# ceTVg\VXf# \a# g[X# Na\gXW#LgTgXf+#BbjXiXe)#g[XeX#\f#fhUfgTag\T_#Xi\WXaVX#g[Tg#WX*VeXTfXf#\a#g[X#ah`UXe#bY#cTg\Xag#i\f\gf#UXZTa#jX__#UXYbeX#g[X#fgTeg#bY#g[X#eXVXff\ba+#>TgT#chU_\f[XW#Ul#g[X#;OG;#\a#XTe_l#/--4#\aW\VTgXW#g[Tg#TaahT_#WbZ#TaW#VTg#i\f\gf#gb#iXgXe\aTe\Taf#WXV_\aXW#f_\Z[g_l#\a#/--3)#Vb`cTeXW#j\g[#/--.)#WXfc\gX#fhUfgTag\T_#Zebjg[#\a#g[X#cXg#cbch_Tg\ba+.#<\Xaa\T_# fheiXlf# VbaWhVgXW# Ul# g[X# ;`Xe\VTa# ;a\`T_#Bbfc\gT_#;ffbV\Tg\ba#[TiX#VbeebUbeTgXW#g[\f#geXaW#TaW#\aW\VTgXW#g[Tg#g[X#WXVeXTfX#\a#ah`UXe#bY#cTg\Xag#i\f\gf#`\Z[g# UX# TVVX_XeTg\aZ+/q3# Me\Xaa\T_# fheiXlf# VbaWhVgXW#Ul#>OG#HXjf`TZTm\aX#YbhaW#f\`\_Te#eXfh_gf+4
M[X#cebfcXVg#g[Tg#g[X#ah`UXe#bY#WbZ#TaW#VTg#i\f\gf#gb#iXgXe\aTel#V_\a\Vf#`Tl#UX#WXVeXTf\aZ#Tg#T#g\`X#j[Xa#g[X#cXg#cbch_Tg\ba#\f#\aVeXTf\aZ#eT\fXf#VbaVXeaf#TUbhg#j[Xg[Xe#cXgf#TeX#ZXgg\aZ#TWXdhTgX#iXgXe\aTel#VTeX)#j[Tg#\`cTVg# g[\f#WXVeXTfX#j\__# [TiX# ba# g[X# XVbab`\V# fgTgX#bY#g[X#iXgXe\aTel#cebYXff\ba)#TaW#j[Xg[Xe#g[X#geXaW#gb*jTeW#YXjXe#iXgXe\aTel#i\f\gf#\f#eXiXef\U_X+
M[X#<TlXe#iXgXe\aTel#VTeX#hfTZX#fghWl#jTf#WXf\ZaXW#gb#Vba"e`#g[X#WXVeXTfX#\a#ah`UXe#bY#cTg\Xag#i\f\gf#g[Tg#[Tf#bVVheeXW#biXe#g\`X)#gb#\WXag\Yl#YTVgbef#eXfcbaf\U_X#Ybe# g[\f#WXVeXTfX)# TaW# gb# \WXag\Yl# fcXV\"V# TVg\baf# g[Tg#Vb`cTa\ba#Ta\`T_#ceTVg\g\baXef#Vbh_W#gT^X#gb#XaVbhe*TZX# `beX# YeXdhXag# iXgXe\aTel# i\f\gf# Ybe# WbZf# TaW# VTgf#gb#eXiXefX#g[X#geXaW+#M[X#ceXfXag#eXcbeg#eXceXfXagf#g[X#XkXVhg\iX#fh``Tel#bY#g[X#fghWlnf#"aW\aZf+
'-805,7
M[X#<TlXe#iXgXe\aTel#VTeX#hfTZX#fghWl# \aib_iXW#1#fgTZXf#bY#eXfXTeV[+#M[X#"efg#fgTZX#jTf#Ta#XkgXaf\iX#eX*i\Xj#bY#_\gXeTgheX#ba#ceTVg\VX#geXaWf)#\aV_hW\aZ#eXiXahX)#geTafTVg\ba#ib_h`X)#V_\Xag#geTY"V)#TaW#YTVgbef#^abja#gb#_\`\g#be#[X_c#\`cebiX#cTg\Xag#i\f\g#ah`UXef+#
M[X#fXVbaW#fgTZX#jTf#T#fXe\Xf#bY#\a*WXcg[#\agXei\Xjf#VbaWhVgXW# j\g[# Vb`cTa\ba# Ta\`T_# ceTVg\VX# bjaXef#
$<-+981;-!7933*6=!5.!80-!"*=-6!!;-8-614*6=!+*6-!97*/-!789,=
@eb`# <eT^^X# =bafh_g\aZ# CaV)# /402# O\__T# =eXX^)# LgX# .1-)# >T__Tf)# MQ#42/01#'Ob_^(8#g[X#HTg\baT_#=b``\ff\ba#ba#OXgXe\aTel#?Vbab`\V#Cf*fhXf#'H=O?C()#.60.#H#GXTV[T`#KW)#LV[Th`UheZ)#CF#3-.40#'@X_fgXW(8#<TlXe# BXT_g[=TeX# ;a\`T_# BXT_g[# >\i\f\ba)# ./4-4# L[TjaXX# G\ff\ba#J^jl)# L[TjaXX)# EL# 33/.3# 'M[b`Tf(8# TaW# Ccfbf# @bejTeW# KXfXTeV[)#./-#KXfXTeV[#Fa)#LgX#/-/)#AhX_c[)#IH#H.A#-<1)#=TaTWT#'L\eXa(+
;WWeXff#VbeeXfcbaWXaVX#gb#Ge+#Ob_^#']b[a9ib_^ba_\aX+Vb`(+
?HIQ!APRICKE!HAQ!MNR!SMDEPGNME!OEEP!PETIEU0!NOIMINMQ!EVOPEQQED!APE!MNR!MECEQQAPIKW! RHNQE!NF! RHE!1@81!NP! RHE!9ARINMAK!2NL$LIQQINM!NM!@EREPIMAPW!3CNMNLIC!6QQSEQ%
TVebff# g[X# Na\gXW# LgTgXf+# Lb`X# bY# g[X# \agXei\Xjf# jXeX#VbaWhVgXW# Tf# f`T__*Zebhc# ebhaWgTU_Xf# '\X)# \a*cXefba#W\fVhff\baf#j\g[#0#be#1#ceTVg\VX#bjaXef#`bWXeTgXW#Ul#T#cebYXff\baT_# \agXei\XjXe(+#M[eXX# fhV[#W\fVhff\baf#jXeX#[X_W# \a#J[\_TWX_c[\T#TaW#0# \a#>T__Tf# \a# _TgX#LXcgX`UXe#/-.-+# Ca# TWW\g\ba)# \a*WXcg[# gX_Xc[baX# \agXei\Xjf# jXeX#VbaWhVgXW#j\g[#bg[Xe#ceTVg\VX#bjaXef#TVebff#g[X#Na\gXW#LgTgXf#gb#cebi\WX#`beX#ZXbZeTc[\V#eXceXfXagTg\ba+#Ca#T__)#01#ceTVg\VX#bjaXef#jXeX#VbagTVgXW)#j\g[#̀ bfg#\agXei\Xjf#_Tfg\aZ#Ta#[bhe#be#`beX+#M[X#ZbT_#bY#g[\f#eXfXTeV[#jTf#gb#haWXefgTaW#[bj#TjTeX#iXgXe\aTe\Taf#jXeX#bY#g[X#WXVeXTfX#\a# i\f\g# ah`UXef)# j[Tg# g[Xl# g[bhZ[g# g[X# VThfXf# jXeX)#j[Xg[Xe#g[Xl#jXeX#TWWeXff\aZ#g[X#geXaW#\a#g[X\e#ceTVg\VXf#TaW#[bj)#TaW#j[Tg#TVg\baf#jXeX#XYYXVg\iX#TaW#\aXYYXVg\iX+
M[X#g[\eW#fgTZX#\aV_hWXW#dhT_\gTg\iX#\agXei\Xjf#j\g[#cXg#bjaXef+#?\Z[g#YbVhf#Zebhcf)#XTV[#Vbaf\fg\aZ#bY#5#cXg#bjaXef)#jXeX#VbaWhVgXW#\a#IVgbUXe#/-.-8#/#YbVhf#Zebhcf#XTV[#jXeX#[X_W# \a#<bfgba8#=b_h`Uhf)#I[\b8#LTa#;agb*a\b)#MXk8#TaW#LTa#@eTaV\fVb+#?YYbegf#jXeX#`TWX#gb#eXVeh\g#WbZ#TaW#VTg#bjaXef#eXceXfXag\aZ#T#j\WX#W\iXef\gl#j\g[#eX*ZTeW#gb#Xg[a\V\gl)#fbV\bXVbab`\V#_XiX_)#TZX)#\aVb`X)#TaW#iXgXe\aTel#hfX# 'XZ)# [XTil# TaW# _\Z[g#hfXef#bY# iXgXe\aTel#fXei\VXf#jXeX#eXceXfXagXW#\a#g[X#YbVhf#Zebhcf(+
M[X#Ybheg[#fgTZX#jTf#T#aTg\baT_#ba_\aX#dhTag\gTg\iX#fheiXl#bY#/).55#NL#WbZ#TaW#VTg#bjaXef+#KXfcbaWXagf#jXeX# WeTja# Yeb`# Ccfbfn# cebce\XgTel# eXfXTeV[# cTaX_# bY#"#.4-)---#^abja#WbZ#bjaXef#TaW#"#.1-)---#^abja#VTg# bjaXef+# M[X# fT`c_X# jTf# eXceXfXagTg\iX# bY# g[X#NL#cXg*bja\aZ#cbch_Tg\ba+#;__# eXfcbaWXagf#jXeX# g[X#ce\*`Tel#cXg#VTeXZ\iXe#\a#g[X#[bhfX[b_W#be#f[TeXW#\a#cXg*VTeX# eXfcbaf\U\_\g\Xf+# Ca#VbaWhVg\aZ# g[X#ba_\aX# fheiXl)#T# WXgT\_XW# dhbgT# c_Ta# UTfXW# ba#;OG;#cXg# bjaXef[\c#fgTg\fg\Vf#jTf#WXiX_bcXW#gb#XafheX#g[Tg#eXfcbafXf#jXeX#eXceXfXagTg\iX#bY#T__#eXZ\baf#TaW#WX`bZeTc[\V#Zebhcf+#LgTg\fg\VT_#`TeZ\a#bY#Xeebe#Ybe#g[X#Xag\eX#fT`c_X#Tg#g[X#62%#Vba"WXaVX#_XiX_#jTf###/+.%8#̀ TeZ\a#bY#Xeebe#Tg#g[X#fcXV\Xf#'WbZ#be#VTg(#_XiX_#jTf###0+-%+
Ca# WXf\Za\aZ# g[X# <TlXe# iXgXe\aTel# VTeX# hfTZX# fghWl)#<TlXe)#<eT^^X)#TaW#H=O?C#Vbafh_gXW#j\g[#fXiXeT_#Uhf\aXff#`TaTZX`Xag# XkcXegf+# M[XfX# \aV_hWXW# Db[a# P+# L_bVh`)#J[>)#cebYXffbe#X`Xe\ghf#bY# g[X#=bk#LV[bb_#bY#<hf\aXff)#Lbhg[Xea#GXg[bW\fg#Na\iXef\gl8#P\__\T`#=eba)#TffbV\TgX#WXTa)# G+# D+# HXX_Xl# LV[bb_# bY# <hf\aXff)# MXkTf# =[e\fg\Ta#Na\iXef\gl8# TaW# T# gXT`# bY# cebYXffbef# Yeb`# ETafTf# LgTgX#Na\iXef\gl#\aV_hW\aZ#>Ti\W#G+#;aWehf)#J[>)#EXi\a#Aj\a*aXe)#J[>)#TaW#D+#<ehVX#Je\aVX)#J[>+#>e+#L_bVh`#\f#Ta#Xk*cXeg#\a#beZTa\mTg\baT_#UX[Ti\be)#TaW#>e+#=eba#\f#Ta#XkcXeg#\a#`Te^Xg\aZ+#M[X#ETafTf#LgTgX#cebYXffbef#TeX#XkcXegf#\a#Vhfgb`Xe#TVdh\f\g\ba#TaW#eXgXag\ba+#;__#[TiX#XkcXe\XaVX#\a#g[X#iXgXe\aTel#"X_W+
>OECIAK!=EONPR
D;OG;r..*-/*-..3SLKrOb_^r..#@\Zr-#MTUrHDKrEDG
Db[a#I+#Ob_^)#<L8#ETeXa#?+#@X_fgXW)#GL)#>OG8#DT`Xf#A+#M[b`Tf)#J[>8#=b_\a#P+#L\eXa)#<;
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 20 of 38
(" >CQ"6CB"<LB?V0";MCAG?I"9CMLOQ" 51>61#">LI"().#"7L%"'&#"6?V"'+#"(&''
&-=!%14,14/7
M[X# <TlXe# iXgXe\aTel# VTeX# hfTZX# fghWl# \WXag\"XW#T# fhece\f\aZ# biXeT__# "aW\aZ7#`Tal# Vb`cTa\ba# Ta\`T_#iXgXe\aTel#ceTVg\VXf#W\W#abg#geTV^#cTg\Xag#i\f\gf8#VbafX*dhXag_l)#bjaXef#W\W#abg#^abj#j[Xg[Xe#g[X#ah`UXe#bY#cTg\Xag#i\f\gf#gb#g[X\e#ceTVg\VXf#jTf#WXVeXTf\aZ#TaW#g[Xl#jXeX#abg#Wb\aZ#Talg[\aZ#gb#TWWeXff#g[X#\ffhX+
M[X#fghWl#\WXag\"XW#3#YTVgbef#g[Tg#TccXTeXW#gb#[TiX#Vbage\UhgXW# gb# g[X# WXVeXTfX# \a# i\f\g# ah`UXef+# M[eXX#jXeX# `Te^Xg*j\WX)# be# Xai\eba`XagT_)# YTVgbef8# 0# jXeX#V_\Xag*We\iXa#YTVgbef+
M[X#0#Xai\eba`XagT_#YTVgbef#jXeX#Tf#Yb__bjf7
#" M[X# /--4q/--6# NL# eXVXff\ba+# M[X# eXVXff\ba# TaW#g[X# eXfh_g\aZ# haX`c_bl`Xag# TaW# haWXeX`c_bl*`Xag#[TW#aXZTg\iX#\`cTVgf#ba#fcXaW\aZ#Ybe#iXgXe\*aTel#fXei\VXf)#XkTVXeUTg\aZ#Ta#Xk\fg\aZ#\ffhX+
#" M[X# YeTZ`XagTg\ba# bY# iXgXe\aTel# fXei\VXf+# M[XeX#jXeX#`beX#cb\agf#bY#VTeX#TaW#T#j\WXe#iTe\Xgl#bY#iXg*Xe\aTel#fXei\VXf#TiT\_TU_X#gb#cXg#bjaXef+
#" Jeb_\YXeTg\ba#bY#PXU#hfTZX+#JXg#bjaXef#YeXdhXag_l#Vbafh_gXW#PXU#fbheVXf#eXZTeW\aZ#cXg#[XT_g[#\ffhXf)#eTg[Xe#g[Ta#VT__\aZ#be#i\f\g\aZ#g[X\e#iXgXe\aTe\Taf+
M[X#0#V_\Xag*We\iXa#YTVgbef#jXeX#Tf#Yb__bjf7
#" CaTWXdhTgX#haWXefgTaW\aZ#bY#g[X#aXXW#Ybe#ebhg\aX#XkT`\aTg\baf+#GTal#cXg#bjaXef#ce\`Te\_l# TffbV\*TgXW#iXgXe\aTel#VTeX#j\g[#iTVV\aTg\baf# '\X)# f[bgf(+#<XVThfX# `Tal# cXgf# W\W# abg# eXdh\eX# TaahT_# iTVV\*aTg\baf)#cXg#bjaXef)#XfcXV\T__l#VTg#bjaXef)#i\f\gXW#g[X\e#iXgXe\aTe\Ta#_Xff#bYgXa+
#" =bfg#bY#iXgXe\aTel#VTeX+#GTal#cXg#bjaXef#XkceXffXW#f[bV^#Tg#g[X#f\mX#TaW#YeXdhXaVl#bY#ce\VX#\aVeXTfXf#Tg#g[X\e#iXgXe\aTel#V_\a\Vf+
#" @X_\aX# eXf\fgTaVX+# <XVThfX# `Tal# VTgf# TZZeXff\iX_l#eXf\fg#UX\aZ#chg#\a#VTee\Xef#TaW#geTafcbegXW#gb#g[X#iXgXe\aTel# V_\a\V# TaW# f[bj# f\Zaf# bY# fgeXff# Whe\aZ#iXgXe\aTel#i\f\gf)#`Tal#VTg#bjaXef#WXYXeeXW#gT^\aZ#g[X\e#Ta\`T_# gb# g[X#iXgXe\aTe\Ta+#M[X#fghWl#YbhaW#g[Tg#1-%#bY#VTgf#[TW#abg#UXXa#gb#g[X#iXgXe\aTe\Ta#j\g[\a#g[X#cTfg#lXTe)#Vb`cTeXW#j\g[#.2%#bY#WbZf+
#LheiXl#eXfcbaWXagf#jXeX#T_fb#fcXV\"V#TUbhg#j[Tg#YTV*
gbef#jbh_W#`T^X#\g#`beX#_\^X_l#g[Tg#g[Xl#jbh_W#i\f\g#g[X#iXgXe\aTe\Ta#`beX#bYgXa+#M[XfX#\aV_hWXW#g[X#Yb__bj\aZ7
#" GbeX#ceXW\VgTU\_\gl# \a# g[X#Vbfg#bY#iXgXe\aTel#VTeX+#JXg#bjaXef#eXfcbaWXW#YTibeTU_l#gb#T#cebcbfT_#g[Tg#g[X\e# iXgXe\aTe\Ta# V_XTe_l# WX"aX# j[Tg# g[X\e# cXg#jbh_W# eXdh\eX# biXe# T# lXTenf# g\`X# TaW# [bj# `hV[#g[XfX# fXei\VXf# jbh_W# Vbfg+# GTal# \aW\VTgXW# g[Xl#jbh_W#T_fb#jX_Vb`X#Ta#bccbegha\gl#gb#cTl#Ybe#iXg*Xe\aTel#fXei\VXf#\a#`bag[_l#\afgT__`Xagf#g[ebhZ[*bhg#g[X#lXTe)#eTg[Xe#g[Ta#\a#T#f\aZ_X#_TeZX#\aib\VX+
#" =b`cXg\g\iX#ce\VXf#Ybe#cebWhVgf#g[Tg#TeX#T_fb#TiT\_*TU_X# g[ebhZ[# bg[Xe# V[TaaX_f+# M[XfX# \aV_hWXW# cXg#YbbW)#fhcc_X`Xagf)#cTeTf\gX#Vbageb_#cebWhVgf)#TaW#bg[Xe#\gX`f+
#" C`cebiXW#VbaiXa\XaVX+#GTal#cXg#bjaXef#\aW\VTgXW#g[Xl#jbh_W#_\^X#gb#[TiX#g[X#iXgXe\aTel#[bfc\gT_#g[Xl#hfXW#bcXa#XTe_\Xe#be#_TgXe#g[Ta#VheeXag_l#TiT\_TU_X+#CagXeXfg\aZ_l)# `Tal# cXg# bjaXef# jXeX# abg# TjTeX#bY# g[X# fXei\VX# [bhef# bY# g[X\e# iXgXe\aTel# V_\a\V# be#j[Xg[Xe#g[X#V_\a\V#[TW#cXg#Webc*bYY#Tccb\ag`Xagf+
)933*6=!5.!%14,14/7
7ACJ!NF!DARA!NM!TIQIRQ!AR! RHE!OPACRICE! KETEKr@be#checbfXf#bY#g[X#ceXfXag#fghWl)#T#i\f\g#jTf#WX"aXW#Tf#Xk*T`\aTg\ba#be#geXTg`Xag#bY#T#WbZ#be#VTg#Tg#T#iXgXe\aTel#ceTVg\VX+#M[\f#WX"a\g\ba#jTf#Vbaf\fgXag#j\g[#[bj#iXgXe*\aTe\Taf#fT\W#g[Xl#cXeVX\iXW#T#i\f\g+#RXg)#\g#UXVT`X#V_XTe#Whe\aZ# \a*WXcg[# \agXei\Xjf#j\g[# ceTVg\VX# bjaXef# g[Tg#`Tal#iXgXe\aTe\Taf#W\W#abg#ebhg\aX_l#`ba\gbe#ah`UXe#bY#cTg\Xag#i\f\gf+#Ca#YTVg)#ba_l#.#bY#g[X#01#iXgXe\aTe\Taf#j[b# jXeX# \agXei\XjXW# ^aXj# j[Xg[Xe# i\f\g# ah`UXef#jXeX#WXVeXTf\aZ#\a#g[X\e#ceTVg\VXf#TaW#Ul#[bj#`hV[+
GTal# iXgXe\aTe\Taf# \aW\VTgXW# g[Tg# g[Xl# eXVbZa\mXW#[Ti\aZ#`Tal#bcXa#Tccb\ag`Xagf#ba#g[X\e#VT_XaWTe#TaW#Ta# biXeT__# WXVeXTfX# \a# eXiXahXf# jXeX# _\^X_l# f\Zaf# bY# T#WXVeXTfX#\a#i\f\g#ah`UXef)#Uhg#g[Xl#[TW#abg#fcXV\"VT__l#XiT_hTgXW#ah`UXe#bY#i\f\gf#gb#g[X\e#ceTVg\VXf+#Gbfg#iXgXe\*aTe\Taf#\agXei\XjXW#jXeX#abg#gT^\aZ#Tal#fcXV\"V#TVg\baf#gb#\aVeXTfX#i\f\g#ah`UXef+#GTal#\aW\VTgXW#g[Tg#g[XeX#jTf#`\a\`T_#Yb__bj*hc#ba#TaahT_#Tccb\ag`Xag#eX`\aWXef#gb#V_\Xagf#TaW# g[Tg# g[XeX#jXeX#ba_l#`bWXfg# XYYbegf)# \Y# Tal)#gb#TggeTVg#aXj#V_\Xagf+#@\aT__l)#cTeg\V\cTagf#\aW\VTgXW#g[Tg#g[Xl#jXeX#`beX#_\^X_l#gb#`ba\gbe#biXeT__# eXiXahXf#TaW#TiXeTZX#geTafTVg\ba#V[TeZXf#g[Ta#i\f\g#ah`UXef#TaW#g[Tg#eT\f\aZ#YXXf#jTf#glc\VT__l#g[X\e#ce\`Tel#be#ba_l#`TaTZX*`Xag#gTVg\V#gb#\`cebiX#biXeT__#eXiXahXf+#Ca#VbageTfg)#jX#UX_\XiX# g[Tg#j[Xa# V_\Xag# WX`TaW# \f# WXVeXTf\aZ)# eT\f\aZ#YXXf#\f#_\^X_l#gb#UX#VbhagXecebWhVg\iX+
6LOACR!NF!RHE!PECEQQINMr@\aW\aZf#fhZZXfgXW#g[Tg#g[X#XVbab`\V#eXVXff\ba#bY#/--4q/--6#_\^X_l#[TW#T#aXZ*Tg\iX#\`cTVg#ba#i\f\g#ah`UXef)#\a#g[Tg#g[X#eXVXff\ba#jTf#g[X#ce\`Tel#VbaVXea#`Xag\baXW#Whe\aZ#\agXei\Xjf#j\g[#ceTVg\VX#bjaXef+#M[X#eXVXff\ba#jTf#T_fb#T#gbc#VbaVXea#T`baZ#cXg#bjaXef+#>he\aZ#g[X#cXg#bjaXe#YbVhf#Zebhcf)#\g#jTf#V_XTe# g[Tg# YXTef#TUbhg#cbgXag\T_# ]bU#TaW# \aVb`X#_bff#T`c_\"XW#VbaVXeaf#TUbhg#g[X#e\f\aZ#Vbfg#bY#iXgXe\*aTel#fXei\VXf+
M[X#\`cTVg#bY#g[X#eXVXff\ba#jTf#Xi\WXag#\a#g[X#ba*_\aX#fheiXl#bY#cXg#bjaXef#Tf#jX__+#JXg#bjaXef#j\g[#_bjXe#[bhfX[b_W#\aVb`Xf#'!#$02)---,l(#TaW#g[bfX#j[b#jXeX#haX`c_blXW#jXeX#_Xff#_\^X_l#gb#[TiX#gT^Xa#g[X\e#cXg#gb#g[X#iXgXe\aTe\Ta#Whe\aZ# g[X#ceXVXW\aZ#lXTe#"4IGSPE!'#!g[Ta#jXeX#bjaXef#j\g[#[\Z[Xe#[bhfX[b_W#\aVb`Xf+#Na*X`c_blXW#VTg#bjaXef#be#VTg#bjaXef#j\g[#_bjXe#[bhfX*[b_W# \aVb`Xf#jXeX# _Xff# _\^X_l# gb#[TiX# gT^Xa# g[X\e#cXg#gb#g[X#iXgXe\aTe\Ta#g[Ta#jXeX#haX`c_blXW#WbZ#bjaXef#be#WbZ#bjaXef#j\g[# _bjXe#[bhfX[b_W# \aVb`Xf+#A\iXa#g[Tg# g[X# haX`c_bl`Xag# eTgX# T_`bfg# WbhU_XW# Whe\aZ#
3GEROC"'W8COACKQ?ECP"LD"BLE"?KB"A?Q"LTKCOP#"AI?PPG!CB"LK"QFC"@?PGP" LD" ?KKR?I" GKALJC" ?KB" CJMILVJCKQ" PQ?QRP#" TFL" F?B" KLQ"Q?HCK"QFCGO"MCQ"QL"QFC"SCQCOGK?OG?K"GK"QFC"M?PQ"VC?O%
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 21 of 38
51>61#">LI"().#"7L%"'&#"6?V"'+#"(&''" >CQ"6CB"<LB?V0";MCAG?I"9CMLOQ" )
g[X#eXVXff\ba)#jX#fhfcXVg#g[Tg#g[XeX#jXeX#YTe#`beX#_bj*#\aVb`X#TaW#haX`c_blXW#cXg#bjaXef#Whe\aZ#g[Tg#cXe\bW+
4PAGLEMRARINM! AMD! EVOAMQINM! NF! TEREPIMAPW! QEP$TICEQrM[X# fXVbaW# `bfg# Vb``ba# VbaVXea# XkceXffXW#Whe\aZ#\agXei\Xjf#j\g[#iXgXe\aTel#ceTVg\VX#bjaXef#jTf#Vb`cXg\g\ba+#Ca#ZXaXeT_)#\g#TccXTeXW#g[\f#jTf#eX_TgXW#gb#T#VbaVXea#g[Tg#cXg#bjaXef#[TiX#`beX#iXgXe\aTel#ceTV*g\VXf#bY#`beX#W\YYXeXag#glcXf#TiT\_TU_X#g[Ta#XiXe#UXYbeX+#JeTVg\VX# bjaXef# jXeX# VbaVXeaXW# TUbhg# Vb`cXg\g\ba#Yeb`# bg[Xe# geTW\g\baT_# iXgXe\aTel# [bfc\gT_f# TaW# XfcX*V\T__l# Yeb`# bg[Xe# glcXf# bY# ceTVg\VX# `bWX_f# g[Tg# g[Xl#cXeVX\iXW#[TW#UXVb`X#`beX#Vb``ba# \a# eXVXag#lXTef+#M[XfX# \aV_hWX#iXgXe\aTel#V_\a\Vf# _bVTgXW# \a#cXg# fgbeXf)#`bU\_X#iTVV\aTg\ba#V_\a\Vf)#iXgXe\aTel#fXei\VXf#cebi\WXW#Ul#Ta\`T_#f[X_gXef#TaW#eXfVhX#bcXeTg\baf)#TaW#fcXV\T_gl#eXYXeeT_#ceTVg\VXf+
Ca#g[X#ba_\aX#fheiXl#bY#cXg#bjaXef)#.0%#\aW\VTgXW#g[Tg#g[Xl#W\W#abg#[TiX#T#ce\`Tel#iXgXe\aTel#V_\a\V)#TaW#.-%#bY#g[bfX#j[b#W\W#[TiX#T#ce\`Tel#iXgXe\aTel#V_\a\V#hfXW#T#ceTVg\VX#bg[Xe#g[Ta#T#geTW\g\baT_#Ta\`T_#[bfc\gT_#"4IGSPE!(#+#IiXeT__)#"#/-%#bY#cXg#bjaXef#\aW\VTgXW#g[Tg#g[Xl#W\W#abg#hfX#T# geTW\g\baT_#iXgXe\aTel#ceTVg\VX#Tf#T#ce\`Tel#fbheVX#bY#iXgXe\aTel#VTeX+
M[X#ah`UXe#bY#iXgXe\aTel#ceTVg\VXf#_bVTgXW#\a#cXg#fgbeXf#TccXTef#gb#[TiX#\aVeXTfXW#eTc\W_l#\a#eXVXag#lXTef+#Ia# g[X#UTf\f# bY# bg[Xe# fghW\Xf# \g# [Tf# WbaX)#<eT^^X# Xf*g\`TgXf# g[Tg#<Ta"X_W#T_baX#[Tf#bcXaXW#Tccebk\`TgX_l#2--#aXj#ceTVg\VXf# \a# g[X#cTfg# .-#lXTef+# <XVThfX#XTV[#aXj#<Ta"X_W#ceTVg\VX#\f#T#fgTeg*hc)#\g#eXceXfXagf#TWWXW#Vb`cXg\g\ba#\a#\gf#`Te^Xg+
M[XeX# \f# _\gg_X# \aYbe`Tg\ba# TiT\_TU_X# ba# g[X# ah`*UXe#bY#fcXV\T_gl#eXYXeeT_#ceTVg\VXf#be#`bU\_X#iTVV\aTg\ba#V_\a\Vf+#<eT^^X#Xfg\`TgXf#g[Tg#g[XeX#TeX#TUbhg#4--#gb#42-#fcXV\T_gl#eXYXeeT_#ceTVg\VXf#\a#g[X#Na\gXW#LgTgXf#TaW#g[Tg#`Tal#bY# g[XfX#[TiX#UXXa#bcXaXW#j\g[\a# g[X#ceXi\bhf#
.-# lXTef+# Gbfg# fcXV\T_gl# ceTVg\VXf# ba_l# gT^X# eXYXeeT_f#Yeb`# ZXaXeT_# ceTVg\VXf# TaW)# Tf# fhV[)# cebi\WX# fXei\VXf#\a#VbbcXeTg\ba#j\g[#cXg#bjaXefn#eXZh_Te#iXgXe\aTe\Taf+#BbjXiXe)# g[\f#`XTaf# g[Tg# g[X# gbgT_#ah`UXe#bY#cTg\Xag#i\f\gf#\a#Tal#Z\iXa#lXTe#\f#fceXTW#biXe#T#_TeZXe#ah`UXe#bY#ceTVg\VXf#TaW#g[Tg#TWiTaVXW#VTeX#g[Tg#`Tl#[TiX#UXXa#cebi\WXW#Ul#ZXaXeT_#ceTVg\VXf# \a# g[X#cTfg# \f#abj#ceb*i\WXW#Tg#fcXV\T_gl#ceTVg\VXf+
GbU\_X#iTVV\aTg\ba#V_\a\Vf#TeX#UX_\XiXW#gb#Vb`cXgX#j\g[# geTW\g\baT_#iXgXe\aTel#ceTVg\VXf)#T_g[bhZ[# g[X#Xk*gXag# gb#j[\V[# g[\f# \f# gehX# \f# haV_XTe+# GbU\_X# iTVV\aT*g\ba#V_\a\Vf#glc\VT__l#fXg#hc#ba#jXX^XaWf#\a#[\Z[*geTY"V#TeXTf#'XZ)#f[bcc\aZ#VXagXe#cTe^\aZ#_bgf(#TaW#TWiXeg\fX#_bj*Vbfg# iTVV\aTg\baf+# Ca# g[X# YbVhf# Zebhcf)#`Tal# cXg#bjaXef#j[b#ebhg\aX_l#gbb^#g[X\e#Ta\`T_f#gb#g[X\e#eXZh*_Te#iXgXe\aTe\Ta#Ybe#bg[Xe#fXei\VXf#eXcbegXW#hf\aZ#̀ bU\_X#V_\a\Vf#Ybe#iTVV\aTg\baf+
JXg# bjaXef# eXfcbaW\aZ# gb# g[X# ba_\aX# fheiXl# eX*cbegXW#g[Tg#/1%#bY#g[X\e#cXgf#[TW#UXXa#TVdh\eXW#Yeb`#Ta\`T_# f[X_gXef# be# cXg# eXfVhX# bcXeTg\baf# "4IGSPE! )#)#j[\V[# jTf# fhUfgTag\T__l# [\Z[Xe# g[Ta# g[X# cXeVXagTZX#eXcbegXW# \a#T#ceXi\bhf#fghWl+T#Mlc\VT__l)#cXgf#TWbcgXW#Yeb`# f[X_gXef# [TiX# UXXa# fcTlXW# be# aXhgXeXW)# iTVV\*aTgXW)# TaW# gXfgXW# Ybe#[XTegjbe`#W\fXTfX# TaW# \agXfg\*aT_#cTeTf\gXf#UXYbeX#UX\aZ#c_TVXW#\a#g[X\e#aXj#[b`Xf+#GTal# bY# g[XfX# fXei\VXf# [TiX# geTW\g\baT__l# UXXa# fb*VT__XW#fgTegXe#fXei\VXf#g[Tg#iXgXe\aTe\Taf#cebi\WXW#TYgXe#V_\Xagf#TVdh\eXW#aXj#chcc\Xf#TaW#^\ggXaf#Yeb`#UeXXW*Xef)#Ye\XaWf)#eX_Tg\iXf)#TaW#bg[Xe#fbheVXf+#Ca#XYYXVg)#geT*W\g\baT_# iXgXe\aTel# [bfc\gT_f# _bfX# Ta# bccbegha\gl# gb#cebi\WX#g[XfX#fXei\VXf#Ybe#cXgf#TWbcgXW#Yeb`#f[X_gXef+#PX#jbeel#g[Tg#\g#j\__#UX#`beX#W\Y"Vh_g#gb#XWhVTgX#aXj#cXg#bjaXef#TUbhg#g[X#aXXW#Ybe#eXZh_Te#iXgXe\aTel#VTeX#\Y#T#iXgXe\aTe\Ta#\f#abg#\a#VbagTVg#j\g[#g[X#cXg#bjaXe#fbba#TYgXe#g[X#cXg#\f#TVdh\eXW+
C`cbegTag_l)# cXg# [XT_g[*VTeX# fXei\VXf# cebi\WXW# Ul#Ta\`T_# f[X_gXef)# `bU\_X# iTVV\aTg\ba# V_\a\Vf)# cXg# fgbeX#V_\a\Vf)#TaW#fcXV\T_gl#eXYXeeT_#ceTVg\VXf#TeX#T__#cebi\WXW#Ul# iXgXe\aTe\Taf+# BbjXiXe)# g[X# fXei\VXf# TeX# cebi\WXW#bhgf\WX# g[X# geTW\g\baT_# iXgXe\aTel# ceTVg\VX# `bWX_+# PX#fhfcXVg#g[Tg#g[X#ceb_\YXeTg\ba#bY#g[XfX#TWWXW#cb\agf#bY#VTeX#jTf#`TWX#cbff\U_X#\a#_TeZX#cTeg#Ul#T#Vbag\ahXW#\a*VeXTfX# \a# g[X#ah`UXe#bY# Vb`cTa\ba#Ta\`T_#iXgXe\aTe*
3GEROC"(W<VMC"LD"SCQCOGK?OV"MO?AQGAC"RPCB"?P"QFC"PLROAC"LD"SCQ$COGK?OV"A?OC"?JLKE"BLE"?KB"A?Q"LTKCOP"TFL"GKBGA?QCB"QF?Q"QFCV"F?SC"?"MOGJ?OV"SCQCOGK?OV"AIGKGA%
3GEROC" )W;LROACP" TFCOC" BLE" ?KB" A?Q" LTKCOP" ?ANRGOCB" QFCGO"MCQP%
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 22 of 38
*" >CQ"6CB"<LB?V0";MCAG?I"9CMLOQ" 51>61#">LI"().#"7L%"'&#"6?V"'+#"(&''
\Taf+#;VVbeW\aZ#gb#WTgT#cebi\WXW#Ul#g[X#;OG;)#Whe\aZ#g[X#.-*lXTe#cXe\bW#Yeb`#.663#g[ebhZ[#/--3)#g[X#ah`*UXe#bY#Vb`cTa\ba#Ta\`T_#iXgXe\aTel#ceTVg\VXf#\aVeXTfXW#Ul#ba_l#..%#'Yeb`#/-).4-#gb#//)060()#Uhg#g[X#ah`UXe#bY#iXgXe\aTe\Taf#ceXWb`\aTag_l#be#XkV_hf\iX_l#ceTVg\V*\aZ# Vb`cTa\ba# Ta\`T_# `XW\V\aX# \aVeXTfXW# Ul# 15%#'Yeb`#0-)/22#gb#11)452(+#>he\aZ#T#f\`\_Te#g\`X#cXe\bW)#g[X#ah`UXe#bY#WbZf# \a# g[X#Na\gXW#LgTgXf# \aVeXTfXW#Ul#03%# TaW# g[X# ah`UXe# bY# VTgf# \aVeXTfXW# Ul# 05%+.# M[X#YTVg#g[Tg#g[X#ah`UXe#bY#ceTVg\g\baXef#[Tf#\aVeXTfXW#YTfg*Xe#g[Ta#g[X#ah`UXe#bY#cXgf#`Tl#Vbage\UhgX#gb#g[X#cXe*VXcg\ba#T`baZ#`Tal#iXgXe\aTe\Taf#g[Tg#Vb`cXg\g\ba#Ybe#iXgXe\aTel#fXei\VXf#\f#Zebj\aZ#`beX#\agXafX+
5PNURH!IM!SQE!NF!RHE!6MREPMER!BW!OER!NUMEPQr;#^Xl# "aW\aZ# Yeb`# g[X# \a*WXcg[# \agXei\Xjf#j\g[# iXgXe\*aTe\Taf#TaW#cXg#bjaXef# \a# g[X#ceXfXag# fghWl# g[Tg#jTf#iXe\"XW#\a#g[X#ba_\aX#fheiXl#bY#cXg#bjaXef#jTf#g[Tg#cXg#bjaXef#WXcXaWXW#_Xff#ba#g[X\e#iXgXe\aTe\Ta#Ybe#iXgXe\*aTel# `XW\VT_# \aYbe`Tg\ba# UXVThfX# bY# g[X# eXTWl# TiT\_*TU\_\gl# bY# \aYbe`Tg\ba# i\T# g[X# CagXeaXg+# Ca# g[X# ba_\aX#fheiXl)# 06%#bY# cXg# bjaXef# TZeXXW#j\g[# g[X# fgTgX`Xag#g[Tg#g[Xl#_bb^#ba_\aX#"efg#\Y#T#cXg#\f#f\V^#be#\a]heXW#TaW#.2%#TZeXXW#j\g[#g[X#fgTgX`Xag#g[Tg#UXVThfX#bY#g[X#Ca*gXeaXg)#g[Xl#eX_l#_Xff#ba#g[X\e#iXgXe\aTe\Ta#"4IGSPE!*#+
MT^Xa#gbZXg[Xe)#bhe#"aW\aZf#fhZZXfgXW#g[Tg#g[X#Ca*gXeaXg#[Tf#[TW#Ta#\`cTVg#ba#cXg#[XT_g[#TaW#cXg#bjaXe#UX[Ti\be+#OXgXe\aTe\Taf#\agXei\XjXW#Ybe#g[X#fghWl#fgTgXW#g[Tg# `Tal# cXg# bjaXef)# TYgXe# Vbafh_g\aZ# g[X# CagXeaXg)#WX_TlXW# gT^\aZ# T# f\V^# be# \a]heXW# cXg# gb# g[X# iXgXe\aTe*\Ta+# Ca# fb`X# \afgTaVXf)# V_\a\VT_# f\Zaf# eXfb_iXW# j\g[\a#T#WTl#be#fb)#fb#bjaXef#W\W#abg#i\f\g#g[X#iXgXe\aTe\Ta#Tg#T__+#Ca#bg[Xe#\afgTaVXf)#g[X#Ta\`T_nf#VbaW\g\ba#jbefXaXW)#aXVXff\gTg\aZ#`beX#XkgXaf\iX#VTeX#baVX#g[X#Ta\`T_#jTf#XiT_hTgXW# Ul# T# iXgXe\aTe\Ta+# ;f# fgTgXW# Ul# baX# XkcXe\*XaVXW#iXgXe\aTe\Ta)#oCn`#fXX\aZ#cXgf#g[eXX#WTlf#f\V^Xe+p
<EPCEORINMQ!NF!RHE!MEED!FNP!PNSRIME!EVALIMARINMQr>he\aZ#g[X#cXg#bjaXe#YbVhf#Zebhc#fXff\baf)#\g#UXVT`X#Tc*cTeXag#g[Tg#`Tal#cXg#bjaXef#TffbV\TgXW#iXgXe\aTel#VTeX#j\g[#iTVV\aTg\baf#TaW#W\W#abg#haWXefgTaW#Tf#eXTW\_l#g[X#aXVXff\gl# Ybe# ebhg\aX# XkT`\aTg\baf+# M[\f# jTf# VbeebUb*eTgXW#Ul#eXfh_gf#bY#g[X#ba_\aX#fheiXl#\a#g[Tg#03%#bY#cXg#bjaXef#TZeXXW#g[Tg#jXeX#\g#abg#Ybe#f[bgf)#g[Xl#jbh_W#abg#gT^X# g[X\e#cXg# gb# g[X# iXgXe\aTe\Ta# "4IGSPE!+#+# L\`\_Te_l)#/1%# TZeXXW# j\g[# g[X# fgTgX`Xag# g[Tg# ebhg\aX# V[XV^hcf#jXeX#haaXVXffTel+
M[X# j\__\aZaXff# gb# YbeXZb# ebhg\aX# XkT`\aTg\baf# jTf#`beX#cebabhaVXW#T`baZ#VTg#bjaXef#g[Ta#T`baZ#WbZ#bja*Xef+#;VVbeW\aZ#gb#g[X#ba_\aX#fheiXl)#ba_l#3-%#bY#VTg#bjaXef#
[TW# gT^Xa# g[X\e# Ta\`T_# gb# g[X# iXgXe\aTe\Ta#\a#g[X#cTfg#lXTe)#j[XeXTf#52%#bY#WbZ#bja*Xef#[TW#gT^Xa#g[X\e#Ta\`T_#gb#g[X#iXgXe\aTe*\Ta#\a#g[X#cTfg#lXTe#"4IGSPE!,#+#;`baZ#g[bfX#j[b#fT\W#g[Tg#g[Xl#jXeX#gT \̂aZ#g[X\e#cXg#gb#g[X#iXgXe\aTe\Ta#_Xff#bYgXa#abj#g[Ta#\a#ceXi\*bhf#lXTef)#30%#bY#WbZ#bjaXef#TaW#35%#bY#VTg#bjaXef#fT\W#g[Xl#W\W#abg#fXX#T#aXXW#gb#gT^X#g[X\e#cXg#gb#g[X#iXgXe\aTe\Ta#Tf#bYgXa8#g[Tg#\f)#g[Xl#fTj#ab#aXXW#Ybe#Ta#TaahT_#XkT`\aTg\ba+
A\iXa# g[Tg# `Tal# cXg# bjaXef# j[b#cTeg\V\cTgXW# \a# g[X# ceXfXag# fghWl# TffbV\*TgXW#iXgXe\aTel#VTeX#j\g[#iTVV\aTg\baf)#jX#fhfcXVg#g[Tg#eXVXag#V[TaZXf#\a#iTVV\aTg\ba#cebgbVb_f#[TiX#[TW#Ta#\`cTVg#ba#ah`UXef#bY#iXgXe\aTel#i\f\gf+#3GEROC"*W=PC"LD"QFC"4KQCOKCQ"DLO"FC?IQF$A?OC"GKDLOJ?QGLK"@V"BLE"?KB"A?Q"LTKCOP%
3GEROC"+W1QQGQRBCP"?JLKE"BLE"?KB"A?Q"LTKCOP"OCE?OBGKE"QFC"KCCB"DLO"OLRQGKC"CU?JGK?QGLKP%
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 23 of 38
51>61#">LI"().#"7L%"'&#"6?V"'+#"(&''" >CQ"6CB"<LB?V0";MCAG?I"9CMLOQ" +
JXg#bjaXef#j[b#eXfcbaWXW#gb#g[X#ba*_\aX# fheiXl# cXeVX\iXW# g[Tg# fb`X# Ta\`T_f#aXXWXW# ebhg\aX# iXgXe\aTel# VTeX# _Xff# YeX*dhXag_l#g[Ta#bg[Xef+#@be#XkT`c_Xf)#fghWl#eXfcbaWXagf# j\g[# cXgf# g[Tg# _\iXW# ce\`Te*\_l#\aWbbef#jXeX#_Xff#_\^X_l#gb#[TiX#gT^Xa#g[X\e#Ta\`T_#gb#g[X#iXgXe\aTe\Ta#\a#g[X#cTfg#lXTe+#F\^Xj\fX)#cXg#bjaXef#j\g[#b_WXe#Ta\*`T_f#jXeX# _Xff# _\^X_l# gb#[TiX# gT^Xa# g[X\e#Ta\`T_#gb#g[X#iXgXe\aTe\Ta#\a#g[X#cTfg#lXTe+#LcXV\"VT__l)#/.%#bY#bjaXef#j\g[#VTgf#!#6#lXTef#b_W#fT\W#g[Xl#jXeX#gT^\aZ#g[X\e#VTg#gb#g[X#iXgXe\aTe\Ta#_Xff#bYgXa#g[Ta#ceXi\bhf_l#"4IGSPE! -#+# M[X# YTVg# g[Tg# `Tal# ZXe\Tge\V#Ta\`T_f# i\f\gXW# T# iXgXe\aTe\Ta# _Xff# bYgXa#g[Ta#lbhaZ#TWh_g#Ta\`T_f#jTf#T_Te`\aZ#gb#g[X#eXfXTeV[#gXT`+
2NQR!NF!CAPErCa#g[X#cXg#bjaXe#YbVhf#Zebhcf)#baX#bY#g[X#YeXdhXag_l#`Xag\baXW#bUfgTV_Xf#gb#iXgXe\aTel#i\f*\gf# jTf# g[X# e\f\aZ# Vbfg# bY# iXgXe\aTel# VTeX+# ;f# baX# cXg#bjaXe#fT\W)#o;__#bY#T#fhWWXa)#g[X#ce\VX#]hfg#f^lebV^XgXW+#Rbh#Vbh_W#Zb#j[Xa#\g#jTf#3-#UhV^f)#abj#C#VTang#ZXg#bhg#Ybe#_Xff#g[Ta#$.2-+p
L\`\_Te#"aW\aZf#jXeX#bUgT\aXW#j\g[#g[X#ba_\aX#fhe*iXl)#j\g[#20%#bY#eXfcbaWXagf#TZeXX\aZ#j\g[# g[X#fgTgX*`Xag#g[Tg#iXgXe\aTel#Vbfgf#TeX#hfhT__l#̀ hV[#[\Z[Xe#g[Ta#XkcXVgXW#"4IGSPE!.#+#@heg[Xe`beX)#/3%#TZeXXW#j\g[#g[X#fgTgX`Xag#g[Tg#g[Xl#Vbaf\fgXag_l#_bb^XW#Ybe#_Xff#XkcXa*f\iX#iXgXe\aTel#bcg\baf#TaW#T#f\`\_Te#cXeVXagTZX#TZeXXW#j\g[#g[X#fgTgX`Xag#g[Tg#g[Xl#jbh_W#fj\gV[#iXgXe\aTe\Taf#\Y#g[Xl#YbhaW#T#_Xff#XkcXaf\iX#baX+
;#cbeg\ba#bY# g[X# ba_\aX# fheiXl# TggX`cgXW# gb#`XT*fheX#cXg#bjaXe#fTg\fYTVg\ba#j\g[#g[X\e#eXZh_Te#iXgXe\aTel#[bfc\gT_#j\g[#eXZTeW#gb#iTe\bhf#Tgge\UhgXf+#IiXeT__)#iXgXe\*aTe\Taf#TaW#g[X\e#fgTYY#fVbeXW#[\Z[)#j\g[#2-%#bY#cXg#bja*Xef# \aW\VTg\aZ# g[Tg# g[Xl#jXeX# Vb`c_XgX_l# fTg\f"XW#j\g[#ab# ebb`# Ybe# \`cebiX`Xag# TaW# Ta#TWW\g\baT_#1-%#fTl*\aZ#g[Xl#jXeX#fTg\f"XW+#OXgXe\aTel#ceTVg\VXf#fVbeXW#[\Z[*Xfg#ba#Ye\XaW_\aXff#bY#g[X#iXgXe\aTe\Taf#TaW#fgTYY#TaW#ba#g[X#eTaZX#bY#fXei\VXf#bYYXeXW+#OXgXe\aTel#ceTVg\VXf#fVbeXW#_bjXfg#ba#iT_hX#bY#fXei\VXf#TaW#cTl`Xag#bcg\baf+
;UMEP! OEPCEORINMQ! NF! AMILAK! QRPEQQr>he\aZ# g[X#cXg#bjaXe#YbVhf#Zebhcf)#\g#UXVT`X#Xi\WXag#g[Tg#VTg#bja*Xef#YbhaW#gT^\aZ#g[X\e#Ta\`T_#gb#g[X#iXgXe\aTe\Ta#[\Z[_l#fgeXffYh_#Ybe#g[X#Ta\`T_#TaW#g[X`fX_iXf+#M[Xl#\aW\VTgXW#g[Tg#g[X\e#VTgf#[\W#j[Xa#g[X#VTg#VTee\Xe#TccXTeXW8#TZZeXf*f\iX_l)#c[lf\VT__l#eXf\fgXW#UX\aZ#chg#\a#g[X#VTee\Xe8#Ve\XW#Whe\aZ#g[X#VTe#be#Uhf#e\WX#gb#g[X#iXgXe\aTel#V_\a\V8#f[bjXW#f\Zaf#bY#fgeXff#TaW#YXTe#\a#g[X#jT\g\aZ#TeXT)#cTeg\Vh_Te_l#j[Xa#haYT`\_\Te#Ta\`T_f)#XfcXV\T__l#WbZf)#jXeX#ceXfXag8#W\fc_TlXW#c[lf\VT_#f\Zaf#bY#gXaf\ba#Whe\aZ#g[X#XkT`\aT*g\ba8#TaW#TVgXW#eX`bgX#TaW#haYe\XaW_l#Ybe#fXiXeT_#WTlf#TY*gXe#eXghea\aZ#[b`X+#GTal#VTg#bjaXef#XkceXffXW#T#WXf\eX#gb# Tib\W# g[X# W\Y"Vh_g\Xf# TaW# hac_XTfTagaXff# TffbV\TgXW#j\g[#Ue\aZ\aZ#g[X\e#VTg#gb#g[X#iXgXe\aTe\Ta+
KXfh_gf#bY# g[X#ba_\aX#fheiXl#[\Z[_\Z[gXW#g[X#\`cbe*gTaVX#bY# g[\f#cebU_X`+#Ia_l#50%#bY#VTg#bjaXef#j[b#eX*fcbaWXW# gb# g[X# fheiXl# fT\W# g[X\e# Ta\`T_# [TW# T# ce\`Tel#iXgXe\aTel#V_\a\V)#Vb`cTeXW#j\g[#6.%#bY#WbZ#bjaXef+#IY#g[bfX#Ta\`T_f#gT^Xa#gb#g[X#iXgXe\aTe\Ta)#WbZf#[TW#i\f\gXW#T#`XTa#bY#/+0#g\`Xf#Whe\aZ#g[X#ceXVXW\aZ#lXTe#TaW#VTgf#[TW#i\f\gXW#T#`XTa#bY#.+4#g\`Xf#Whe\aZ#g[X#ceXVXW\aZ#lXTe+#Ca#
`XTfhe\aZ#cXg#bjaXe#Tgg\ghWXf#gbjTeW#gT^\aZ#g[X\e#Ta\`T_#gb#g[X#iXgXe\aTe\Ta)#VTg#bjaXef#[TW#`beX#aXZTg\iX#eTg\aZf#g[Ta#WbZ#bjaXef#Ybe#XiXel#Tgge\UhgX)#\aV_hW\aZ#fhV[#\gX`f#Tf#oPbh_W#abg#gT^X#`l#cXg#gb#g[X#iXg# \Y#iTVV\aTg\ba#abg#aXXWXWp#TaW#oGl#cXg#[TgXf#Zb\aZ#gb#g[X#iXgp#"4IGSPE!/#+
<NREMRIAK!QNKSRINMQrM[X#<TlXe#iXgXe\aTel#VTeX#hf*TZX#fghWl#XkT`\aXW#abg#ba_l#j[l#cXg#bjaXef#jXeX#gT^*\aZ#g[X\e#Ta\`T_f#gb#g[X#iXgXe\aTe\Ta#_Xff#bYgXa)#Uhg#T_fb#j[Tg#iXgXe\aTe\Taf#Vbh_W#Wb#gb#\aVeXTfX#g[X#YeXdhXaVl#bY#cTg\Xag#i\f\gf+#;f#T#cTeg#bY#g[X#ba_\aX#fheiXl)#cXg#bja*Xef#jXeX#Tf^XW#haWXe#j[Tg#V\eVh`fgTaVXf# g[Xl#jbh_W#gT^X#g[X\e#cXg#gb#g[X#iXgXe\aTe\Ta#`beX#bYgXa+#@bhe#Tgge\*UhgXf#fVbeXW#[\Z[Xfg#Ubg[#T`baZ#WbZ#TaW#VTg#bjaXef)#T_g[bhZ[#\a#f_\Z[g_l#W\YYXeXag#beWXe#"4IGSPE!'
#" CY#C#^aXj#C#Vbh_W#ceXiXag#cebU_X`f#TaW#XkcXaf\iX##geXTg`Xag#_TgXe+
#" CY#C#jTf#Vbai\aVXW#\g#jbh_W#[X_c#`l#cXg#_\iX#_baZXe+#" CY#XTV[#i\f\g#jTf#_Xff#XkcXaf\iX+#" CY#C#eXT__l#UX_\XiXW#`l#cXg#aXXWXW#XkT`\aTg\baf##
`beX#bYgXa+
3GEROC"-W2F?KEC"GK"DOCNRCKAV"LD"SCQCOGK?OV"A?OC"OCMLOQCB"@V"A?Q"LTKCOP"?P"?"DRKAQGLK"LD"?EC"LD"QFC"A?Q%
3GEROC",W<GJC"OCMLOQCB"@V"BLE"?KB"A?Q"LTKCOP"PGKAC"QFCGO"MCQ"F?B"I?PQ"@CCK"PCCK"@V"?"SCQCOGK?OG?K%
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 24 of 38
," >CQ"6CB"<LB?V0";MCAG?I"9CMLOQ" 51>61#">LI"().#"7L%"'&#"6?V"'+#"(&''
;__#1#bY#g[XfX#Tgge\UhgXf#eTgXW#fhUfgTag\T__l#[\Z[Xe#g[Ta#g[X#bg[Xef#_\fgXW)#\aV_hW\aZ#Ye\XaW_\aXff)#VbaiXa\XaVX)#TaW#c_XTfTagaXff#bY# g[X#iXgXe\aTel#ceTVg\VX8# f[begXe#Tccb\ag*`Xagf8#_Xff#fgeXff#ba#g[X#Ta\`T_8#TaW#bg[Xe#YTVgbef+#M[XfX#"aW\aZf# fhZZXfgXW#cXg#bjaXef#aXXW# gb# Yh__l#haWXefgTaW#g[X#[XT_g[# \`c_\VTg\baf# Ybe# g[X\e#cXgf#TaW# g[X#XVbab`\V#UXaX"gf#Ybe#g[X`fX_iXf#UXYbeX#g[Xl#j\__# \aVeXTfX#g[X#YeX*dhXaVl#j\g[#j[\V[#g[Xl#i\f\g#g[X\e#iXgXe\aTe\Ta+
Ca# TWW\g\ba)# Whe\aZ# g[X# \a*WXcg[# \agXei\Xjf# j\g[# iXg*Xe\aTel#ceTVg\VX#bjaXef#TaW#g[X#cXg#bjaXe#YbVhf#Zebhcf)#g[X#eXfXTeV[#gXT`#Xkc_beXW#Tf#`Tal#Tf#/-#fcXV\"V#TVg\baf#g[Tg#iXgXe\aTe\Taf#Vbh_W#gT^X#gb#\aVeXTfX#cTg\Xag#i\f\gf+#Lb`X#bY#g[X#\WXTf#jXeX#fhZZXfgXW#Ul#fghWl#cTeg\V\cTagf#TaW#bg[Xef#Ul#g[X#eXfXTeV[#gXT`+#>he\aZ#g[X#cXg#bjaXe#YbVhf#Zebhcf)#g[\f#_\fg#bY#cbgXag\T_#\a\g\Tg\iXf#g[Tg#jXeX#XiT_hTgXW#\a#g[X#ba_\aX#fheiXl#jTf#aTeebjXW#gb#.-+#M[Xl#\aV_hWXW#g[X#Yb__bj\aZ7
#" ;#Yh__*lXTe#[XT_g[#cebZeT`#Ybe#lbhe#cXg#WXiX_bcXW#Ul#lbhe#iXgXe\aTe\Ta#bhg_\a\aZ#j[Tg#lbhe#cXg#aXXWf)#j[Xa#lbh#f[bh_W#i\f\g#g[X#iXgXe\aTel#V_\a\V)#j[Tg#gb#_bb^#bhg#Ybe)#TaW#[bj#gb#^XXc#lbhe#cXg#[XT_g[l+
#" ;#cTl`Xag#c_Ta#haWXe#j[\V[#lbh#jbh_W#UX#U\__XW#\a#XdhT_#`bag[_l# \afgT__`Xagf# Ybe#T#lXTenf# eXZh_Te#iXgXe\aTel# fXei\VXf# g[Tg# jbh_W# VbiXe# T__# bY# lbhe#cXgnf#ebhg\aX#[XT_g[#VTeX#Ybe#T#Yh__#lXTe)#dhT_\Yl#lbh#Ybe# VXegT\a# W\fVbhagf# be# YeXX# i\f\gf)# TaW# X_\`\aTgX#_TeZX# \aib\VXf# Tg# g[X# g\`X# bY# i\f\g+# Cg# jbh_W# abg#VbiXe#haXkcXVgXW#i\f\gf#Ybe#f\V^aXff#be#\a]hel+
#" ;#jXUf\gX# Ybe# lbhe#cXgnf# V_\a\V# g[Tg# T__bjf#lbh# gb#fXX# TiT\_TU_X# Tccb\ag`Xag# g\`Xf#ba_\aX# TaW#Ubb^#Ta#Tccb\ag`Xag+
#" ;# fcXV\T_)# cTffjbeW*cebgXVgXW# cTZX# ba# lbhe#iXgXe\aTe\Tanf#jXUf\gX#g[Tg#[Tf#T__#bY#g[X#\aYbe`Tg\ba#TaW#`XW\VT_#eXVbeWf#Ybe#lbhe#cXg+
#" ?kgXaWXW# Uhf\aXff# [bhef# Ybe# Tccb\ag`Xagf)# \a*V_hW\aZ# TiT\_TU\_\gl# bY# XTe_\Xe# TaW# _TgXe# Tccb\ag*`Xagf# XTV[# WTl# Tf# jX__# Tf# Tccb\ag`Xagf# ba# g[X#jXX^XaW+
#" M[X#TU\_\gl#Ybe#lbh#gb#Webc#bYY#lbhe#cXg#\a#g[X#̀ bea*\aZ#TaW#c\V^#\g#hc#TYgXe#\gf#Tccb\ag`Xag+
#" CaYbe`Tg\ba# TUbhg# "aTaV\aZ# cebZeT`f# Ybe# iXgXe\*aTel#VTeX#fhV[#Tf#\afgT__`Xag#cebZeT`f)#cXg#[XT_g[#\afheTaVX)#be#fcXV\T_#"aTaV\aZ#Ybe#X`XeZXaV\Xf#be#_TeZXe*g[Ta*beW\aTel#Vbfgf+
#" Je\VXf#Ybe#cebWhVgf#'XZ)#!XT#TaW#g\V^#cebWhVgf)#fcX*V\T_gl# cXg# YbbWf)# TaW# fhcc_X`Xagf(# g[Tg# TeX# Vb`*cXg\g\iX#j\g[#j[Tg#lbh#"aW#X_fXj[XeX+
#" =XegT\a#WTlf#be#[bhef#eXfXeiXW#Ybe#VTg*ba_l#be#WbZ*ba_l# Tccb\ag`Xagf# gb# Tib\W# XaVbhagXef# UXgjXXa#VTgf#TaW#WbZf+
#" ;#c_Tl#TeXT#j\g[#gblf#be#ZT`Xf#Ybe#V[\_WeXa+
GbeX#g[Ta#2-%#bY#T__#WbZ#TaW#VTg#bjaXef#eTgXW#5#bY#g[X#VbaVXcgf#fb`Xj[Tg#be#XkgeX`X_l#iT_hTU_X+#M[X#ba_l#baXf#
3GEROC"/W1QQGQRBCP"?JLKE"BLE"?KB"A?Q"LTKCOP"OCE?OBGKE"Q?HGKE"QFCGO"MCQ"QL"QFC"SCQCOGK?OG?K%
3GEROC".W1QQGQRBCP"?JLKE"BLE"?KB"A?Q"LTKCOP"OCE?OBGKE"QFC"ALPQ"LD"SCQCOGK?OV"A?OC%
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 25 of 38
51>61#">LI"().#"7L%"'&#"6?V"'+#"(&''" >CQ"6CB"<LB?V0";MCAG?I"9CMLOQ" -
g[Tg#jXeX#eTgXW#Tf#iT_hTU_X#Ul#!#2-%#bY#cXg#bjaXef#jXeX#eXfXei\aZ#VXegT\a#WTlf#be#[bhef#Ybe#VTg*ba_l#be#WbZ*ba_l#Tc*cb\ag`Xagf#gb#Tib\W#XaVbhagXef#UXgjXXa#VTgf#TaW#WbZf#TaW#VeXTg\aZ#T#c_Tl#TeXT#j\g[#gblf#be#ZT`Xf#Ybe#V[\_WeXa+
Ca#f[beg)#`bfg#cXg#bjaXef#j[b#eXfcbaWXW#gb#g[X#ba_\aX# fheiXl# YbhaW# `bfg# bY# g[X# fXei\VXf# TggeTVg\iX+#Mb# XiT_hTgX# g[X# VbaVXcgf# Yheg[Xe)# eXfcbaWXagf# jXeX#Tf^XW#gb#\WXag\Yl#g[X#0#fXei\VXf#g[Tg#jbh_W#`bfg#_\^X_l#
`bg\iTgX# g[X`# gb# gT^X# g[X\e#cXg# gb# g[X#iXgXe\aTe\Ta#`beX# bYgXa+# @bhe# fXei\VXf#jXeX#_\fgXW#`bfg#YeXdhXag_l#Ubg[#Ul#WbZ#bjaXef#TaW#Ul#VTg#bjaXef)#T_g[bhZ[#\a#f_\Z[g_l#W\YYXeXag#beWXe# "4IGSPE!''#+# Ca#ZXaXeT_)# fXei\VXf# eTgXW# [\Z[Xfg# Ul# g[X#cXg#bjaXef#\aV_hWXW#g[bfX#g[Tg#Vbage\U*hgXW#gb#VbaiXa\XaVX)#XVbab`l)#TaW#ceX*W\VgTU\_\gl#bY#Vbfgf+
#54+2971547
;_g[bhZ[# g[X# ah`UXe# bY# cTg\Xag#i\f\gf# gb#iXgXe\aTel#[bfc\gT_f#TccXTef# gb#[TiX# UXXa# WXVeXTf\aZ# Ybe# fXiXeT_# lXTef)#g[X#ceXfXag#fghWl#YbhaW#g[Tg#`bfg#\aW\*i\WhT_#iXgXe\aTel#ceTVg\VXf#W\W#abg#`ba*\gbe#i\f\g#ah`UXef#TaW#jXeX#haTjTeX#bY#fcXV\"V#V[TaZXf#\a#i\f\g#YeXdhXaVl+
Ihe#"aW\aZf#\aW\VTgXW#g[Tg#0#YTVgbef#\a# g[X# Uhf\aXff# Xai\eba`Xag# 'XZ)# g[X#/--4q/--6# NL# eXVXff\ba)# Ta# XkcTaWXW#TaW#YeTZ`XagXW#TeeTl#bY#iXgXe\aTel#ceTV*g\VX#`bWX_f)#TaW#\aVeXTfXW#hfX#bY#g[X#Ca*gXeaXg#Ul#cXg#bjaXef(#Vbage\UhgXW#gb#g[X#eXWhVg\ba#\a#ah`UXe#bY#cTg\Xag#i\f\gf#gb#geTW\g\baT_#iXgXe\aTel#[bfc\gT_f+#Ca#TWW\*g\ba)#0#V_\Xag*We\iXa#YTVgbef#TccXTeXW#gb#Vbage\UhgX#gb#g[X#WXVeXTfX#\a#i\f\g#ah`*UXef+# LcXV\"VT__l)#`Tal# cXg# bjaXef# W\W#abg# gb# gT^X# g[X\e# cXgf# gb# g[X# iXgXe\aTe*\Ta#be#gbb^#g[X`#_Xff#bYgXa#UXVThfX#g[Xl#W\W#abg#haWXefgTaW#g[X#aXXW#Ybe#be#iT_hX#bY# ebhg\aX# jX__aXff# XkT`\aTg\baf)# g[Xl#g[bhZ[g#iXgXe\aTel#Vbfgf#jXeX# gbb#[\Z[)#be# g[Xl# jXeX# haj\__\aZ# gb# chg# hc# j\g[#g[X#fgeXff# gb# g[X#Ta\`T_#TaW#g[X`fX_iXf#\aib_iXW#j\g[#gT^\aZ#g[X\e#cXg#gb#g[X#iXg*Xe\aTel#[bfc\gT_+
Ihe# "aW\aZf# T_fb# fhZZXfgXW# g[Tg#cXg#bjaXef#jbh_W#i\f\g# g[X#iXgXe\aTe\Ta#`beX# bYgXa# \Y# g[Xl# V_XTe_l# haWXefgbbW#g[X#[XT_g[#UXaX"gf#Ybe#g[X\e#cXgf#TaW#g[X#XVbab`\V# UXaX"gf# Ybe# g[X`fX_iXf# 'XZ)#Tib\W\aZ#XkcXaf\iX#geXTg`Xagf#_TgXe(#Tf*fbV\TgXW# j\g[# fhV[# i\f\gf+# @heg[Xe`beX)#cXg#bjaXef#\aW\VTgXW# g[Xl#jbh_W#UX#\a*V_\aXW# gb# gT^X# g[X\e# cXgf# `beX# bYgXa# \Y#Wb\aZ# fb# jXeX# `beX# VbaiXa\Xag# be# _Xff#XkcXaf\iX+
@\aT__l)#bhe#"aW\aZf# fhZZXfgXW# g[Tg#iXgXe\aTe\Taf#Vbh_W#\aVeXTfX#g[X#YeXdhXa*Vl#bY#cTg\Xag#i\f\gf#g[ebhZ[#g[X#hfX#bY#g[X#Yb__bj\aZ7
#" ?kgXaW\aZ#Uhf\aXff#[bhef+#" <\__\aZ# ebhg\aX#TaahT_#jX__aXff# fXe*
i\VXf#\a#XdhT_#`bag[_l#\afgT__`Xagf+#" Jebi\W\aZ#Vb`cXg\g\iX#ce\VXf#Ybe#cebW*
hVgf# fhV[# Tf# cXg# YbbW)# fhcc_X`Xagf)#TaW#cTeTf\gX#Vbageb_#cebWhVgf#g[Tg#TeX#TiT\_TU_X#g[ebhZ[#bg[Xe#V[TaaX_f+
3GEROC"''W2LKACMQP"QF?Q"BLE"?KB"A?QP"LTKCOP"GKBGA?QCB"TLRIB"JLPQ"IGHCIV"A?RPC"QFCJ"QL"Q?HC"QFCGO"MCQP"QL"QFC"SCQCOGK?OG?K"JLOC"LDQCK%
3GEROC"'&W9C?PLKP"QF?Q"BLE"?KB"A?Q"LTKCOP"TLRIB"Q?HC"QFCGO"MCQP"QL"QFC"SCQCOGK?OG?K"JLOC"LDQCK%
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 26 of 38
." >CQ"6CB"<LB?V0";MCAG?I"9CMLOQ" 51>61#">LI"().#"7L%"'&#"6?V"'+#"(&''
#" >XiX_bc\aZ# T# Yh__*lXTe# [XT_g[# c_Ta# g[Tg# bhg_\aXf#j[Tg#g[X#cXg#aXXWf)#j[Xa#g[X#bjaXe#f[bh_W#Ue\aZ#g[X#cXg# gb# g[X#iXgXe\aTel# V_\a\V)#j[Tg# gb# _bb^#bhg#Ybe)#TaW#[bj#gb#^XXc#g[X#cXg#[XT_g[l+
T+## /--6#AT__hc#fghWl#bY# g[X#!XT#&#g\V^#Vbageb_#cebWhVg#`Te^Xg)#Gh_g\*fcbafbe#LheiXlf#CaV)#Je\aVXgba)#HD+
(-.-6-4+-7
.+# ;OG;+#'#&#!6,9!5=4,78/06!(4+!+,35.7(6/0*!85;7*,)551+#LV[Th`*UheZ)#C__7#;OG;)#/--4+
/+# ;`Xe\VTa#;a\`T_#Bbfc\gT_#;ffbV\Tg\ba+#%04(4*0(2!(4+!675+;*90<"09>!6;28,650498$!<09(2!89(90890*8!-57!>5;7!<,9,704(7>!67(*90*,+#/aW#XW+#FT^XjbbW)#=b_b7#;;B;#JeXff)#/--.+
0+# ;`Xe\VTa#;a\`T_#Bbfc\gT_#;ffbV\Tg\ba+#%04(4*0(2!(4+!675+;*90<"09>!6;28,650498$!<09(2!89(90890*8!-57!>5;7!<,9,704(7>!67(*90*,+#0eW#XW+#FT^XjbbW)#=b_b7#;;B;#JeXff)#/--0+
1+# ;`Xe\VTa#;a\`T_#Bbfc\gT_#;ffbV\Tg\ba+#%04(4*0(2!(4+!675+;*90<"09>!6;28,650498$!<09(2!89(90890*8!-57!>5;7!<,9,704(7>!67(*90*,+#1g[#XW+#FT^XjbbW)#=b_b7#;;B;#JeXff)#/--2+
2+# ;`Xe\VTa#;a\`T_#Bbfc\gT_#;ffbV\Tg\ba+#%04(4*0(2!(4+!675+;*90<"09>!6;28,650498$!<09(2!89(90890*8!-57!>5;7!<,9,704(7>!67(*90*,+#2g[#XW+#FT^XjbbW)#=b_b7#;;B;#JeXff)#/--4+
3+# ;`Xe\VTa#;a\`T_#Bbfc\gT_#;ffbV\Tg\ba+#%04(4*0(2!(4+!675+;*90<"09>!6;28,650498$!<09(2!89(90890*8!-57!>5;7!<,9,704(7>!67(*90*,+#3g[#XW+#FT^XjbbW)#=b_b7#;;B;#JeXff)#/--6+
4+# >OG# HXjf`TZTm\aX+# /--6# ge\Xaa\T_# eXcbeg)# fgTgX# bY# g[X# iXg*Xe\aTel# cebYXff\ba+# ;iT\_TU_X# Tg7# iXgXe\aTelaXjf+Wi`03-+Vb`,Wi`,;eg\V_XLgTaWTeW,;eg\V_X,WXgT\_,262545+# ;VVXffXW# Dh_# /4)#/-.-+
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 27 of 38
+789813'
FS! *TRJNFRR'! 1N! SIF
PBRS"! *BXFQ! )NJMBL
0FBLSIZR! PQOETDSR
VFQF! ONLX! BUBJLBCLF
SIQOTHI!B!UFSFQJNBQJ#
BN$! >IFN!EJE! SIFRF!PQOETDSR
CFDOMF! BUBJLBCLF! GOQ! RBLF! CX
PFS!RSOQFR(!
,BN! 7FJYFQ' Dd! A[XhkWho! e\! j^_i
o[Wh)! m[! WddekdY[Z! j^[! [nfWd*
i_ed!e\!ekh!iWb[i!Y^Wdd[b!\eh!<ZlWdjW][!Oef_YWb!Nebkj_ed!WdZ!F6
<ZlWdj_n!je!_dYbkZ[!f[j!if[Y_Wbjo!h[jW_b[hi+!Nec[!Ddj[hd[j!WdZ
Xh_Ya*WdZ*cehjWh!h[jW_b[hi!^Wl[!e\\[h[Z!j^[i[!fheZkYji!\eh!i[l*
[hWb!o[Whi)!Xkj!edbo!j^_i!o[Wh!^Wl[!j^[o!X[[d!WlW_bWXb[!je!h[jW_b*
[hi! m_j^! j^[! Z_h[Yj! ikffehj! e\! =Wo[h! <d_cWb! C[Wbj^+! O^_i! _i
_cfehjWdj!X[YWki[! _j!Wiikh[i! h[jW_b[hi! j^Wj! j^[o!Wh[!fhel_Z_d]
f[j!emd[hi!m_j^!fheZkYj!Z_h[Yj!\hec!j^[!cWdk\WYjkh[h!XWYa[Z
Xo!ekh!\kbb!j[Y^d_YWb!ikffehj+!
7*'! >IBS! RFSR! 2&! )EUBNSJW! BNE! )EUBNSBHF! ;OPJDBL
9OLTSJON!BPBQS!GQOM!OSIFQ!GLFB!BNE!SJDK!SQFBSMFNSR(
7FJYFQ' N_dY[!_ji!_djheZkYj_ed)!<ZlWdjW][!^Wi![d`eo[Z!j^[!h[Y*
ecc[dZWj_ed! e\! l[j[h_dWh_Wdi! mehbZm_Z[! \eh! j^[! Yedjheb! e\
\b[Wi!ed!Ze]i!WdZ!YWji+!O^Wjvi!el[h!.1!o[Whi)!WdZ!_j!Yedj_dk[i!je
X[!h[Yecc[dZ[Z!Xo!l[j[h_dWh_Wdi!jeZWo!X[YWki[!e\!^em![\\[Y*
j_l[!_j!_i!WdZ!̂ em!iWj_i\_[Z!j^[_h!Yb_[dji!̂ Wl[!X[[d!m_j^!j^[!fheZ*
kYj+!F6!<ZlWdj_n!'\eh!Ze]i!edbo()!_djheZkY[Z!_d!/--0)!^Wi!Wbie
]Whd[h[Z! j^[! h[Yecc[dZWj_ed! e\! l[j[h_dWh_Wdi! WhekdZ! j^[
mehbZ!X[YWki[!e\!_ji!WX_b_jo!je!dej!edbo!a_bb!Xkj!Wbie!h[f[b!\b[Wi)
j_Yai!WdZ!ceigk_je[i+!R_j^!j^[!_dYh[Wi[Z!WmWh[d[ii!Wced]!f[j
emd[hi! WXekj! j^[! Z_i[Wi[*YWki_d]! eh]Wd_ici! j^Wj! \b[Wi)! j_Yai
WdZ! ceigk_je[i! YWd! YWhho)! j^[! h[f[bb[dYo! e\\[h[Z! Xo! F6
<ZlWdj_n!̂ Wi!fhel[d!je!X[!W!m[bYec[!\[Wjkh[!m^_Y^!i[ji!_j!WfWhj
\hec!ej^[h!fheZkYji+!
7*'! 0OV! DBN! PFS! RPFDJBLSX! RSOQFR! FGGFDSJUFLX! DOMPFSF
VJSI!UFSFQJNBQX!DLJNJDR!JN!RFLLJNH!SIFRF!PQOETDSR(!
7FJYFQ' =o! Xk_bZ_d]! WmWh[d[ii
WdZ!cWa_d]! \b[W!WdZ! j_Ya!Yedjheb
Wd! [ii[dj_Wb! fWhj! e\! f[j! YWh[! \eh
oekh! Ykijec[hi+! Q_i_j_d]! j^[! l[j*
[h_dWh_Wd!ed!W!h[]kbWh!XWi_i!_i!ij_bb
j^[!i_d]b[!ceij!_cfehjWdj!j^_d]!W
f[j!emd[h!YWd!Ze!\eh!j^[!̂ [Wbj^!e\
j^[_h! f[j+! O^Wj! iW_Z)! f[j! emd[hi
l_i_j! f[j! if[Y_Wbjo! h[jW_b[hi! ceh[
\h[gk[djbo!j^Wd!j^[o!Ze!j^[_h!l[j*
[h_dWh_Wd!ed!Wd!WddkWb!XWi_i!je!fkhY^Wi[!\eeZ!WdZ!ej^[h![ii[d*
j_Wb! _j[ci+!R^_b[! [nf[hji! b_a[! j^[!>ecfWd_ed!<d_cWb!KWhWi_j[
>ekdY_b!h[Yecc[dZ!j^Wj!f[j!emd[hi!Wffbo!\b[W!WdZ!j_Ya!Yedjheb
o[Wh*hekdZ!_d!ceij!Wh[Wi!e\!j^[!Yekdjho)!h[i[WhY^!i^emi!j^Wj!ed
Wl[hW][!f[j!emd[hi!edbo!Wffbo!WXekj!ed[*j^_hZ!e\!j^[!h[Yec*
c[dZ[Z!Zei[i+!R_j^!Z_h[Yj!ikffehj!\hec!=Wo[h!<d_cWb!C[Wbj^)
m[!YWd!^[bf!f[j!h[jW_b[hi!b[l[hW][!ekh![nf[hj_i[!_d!fWhWi_j[!fh[*
l[dj_ed!WdZ!jh[Wjc[dj!je!][j!j^[!c[iiW][!je!j^[_h!Ykijec[hi+!
7*'!>IBS!BQF!ROMF!OG!SIF!CJHHFRS!MJRSBKFR!SIBS!QFSBJLFQR
MBKF!JN!RFLLJNH!SIFRF!PQOETDSR(
7FJYFQ' O^[!X_]][ij!ed[!_i!Wiikc_d]!j^Wj!f[j!emd[hi!edbo!d[[Z
\b[W!Yedjheb!edY[!j^[o!i[[!\b[Wi!ed!j^[_h!f[ji+!O^[!h[Wb_jo!_i!j^Wj
WZkbj!\b[Wi!cWa[!kf!edbo!\_l[!f[hY[dj!e\!j^[!jejWb!fefkbWj_ed!e\
\b[Wi!_d!j^[![dl_hedc[dj!Wj!Wdo!ed[!j_c[)!ie!Xo!j^[!j_c[!WZkbji
Wh[!i[[d)!_jvi!jee!bWj[!je!fh[l[dj!W!fej[dj_Wb!_d\[ijWj_ed+!
<dej^[h!Yecced!c_ijWa[!_i!Wiikc_d]!j^Wj!f[j!emd[hi!edbo
^Wl[!je!mehho!WXekj!\b[Wi!WdZ!j_Yai!m^[d!j^[!m[Wj^[h!_i!mWhc+
R^_b[! _jvi! jhk[! j^Wj! \b[Wi! h[gk_h[! Y[hjW_d! j[cf[hWjkh[! WdZ
^kc_Z_jo!hWd][i!je!fheb_\[hWj[!ekjZeehi)![l[d!Zkh_d]!j^[!YebZ*
[h!fWhji!e\!j^[!o[Wh!m[!b_a[!je!a[[f!ekh!^ec[i!Wj!`kij!j^[!b[l[bi
j^Wj!\b[Wi!b_a[+!O^[h[\eh[)!ki_d]!j^[!ekjZeeh!j[cf[hWjkh[!Wi!W
]k_Z[!\eh!m^[d!je!ijWhj!eh!ijef!\b[W!Yedjheb!YWd!X[!c_ib[WZ_d]+
Dd!WZZ_j_ed)!ej^[h!fWhWi_j[i!b_a[!j_Yai!cWo!X[!WYj_l[!Wj!j_c[i!e\
j^[!o[Wh!m^[d!\b[Wi!Wh[!dej+!O^[!Xejjec!b_d[!_i)!fh[l[dj_ed!_i
a[o!WdZ!fhWYj_Y_d]!o[Wh*hekdZ!Yedjheb!_i!j^[!X[ij!j^_d]!oekh!Yki*
jec[hi!YWd!Ze!\eh!j^[_h!f[ji+ '%
'C!'9J6CH6=;!<DF!1;H!3HDF;G9O\!FSWhS &̀![O`YSbW\U![O\OUS`!T]`!7OgS`!6\W[OZ!>SOZbV&!RWaQcaaSa!bVS!Q][^O\gma![]dS
W\b]!^Sb!a^SQWOZbg!ab]`Sa!eWbV!Wba!^]^cZO`!TZSO'!O\R!bWQY'Q]\b`]Z!^`]RcQba(!
K
&#( ")'$%#''!! &*)*+(*,!$"#" -* ---!)$+",*%'$**!#(&
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 32 of 38
@FLDOMF
<JHN 2N Z ,QFBSF *DDOTNS Z ;FOQEFQ Z 6X *DDOTNS Z ,ONSBDS >R
!%% "$( #)&$'
-FNSBL a .BQ a .XF a /LFB BNE =JDK a 1FBQSVOQM a 3OJNSR a 6FEJDBSJONR a 9BJN a 9FS /OOE a <KJN ! ,OBS a <TPPLJFR a ?JSBMJNR a <*5. a 9FS .ETDBSJON
5VTM - 3SMI IUL BQKR
+QOVRF +X
+QBNE
9QJDF
<XMPSOMR
NSMI MOOZNSMI SIY]IMNSMIZ
TVZX\Q[VMZ[QKRZ
1FBLSI 2RRTFRNSMI WYM]MU[QVU
NSMI YMSQMNQ[KPQUO[QKRZ
2NHQFEJFNSRNQWYVUQS
QTQLIKSVWYQLS\NMU\YVU
WMYTM[PYQUW`YM[PYQUZZ&TM[PVWYMUM
,OMPBQF
9QOETDSR
3YVU[SQUM >S\Z
+'( 2_WMY[
@I[QUO
0VTNVY[QZ
*'( 2_WMY[
@I[QUO
. / 0 1 21 2 3 4 5 6 7 8 9 ; <; <
= >= > ? @? @ A B C D E F G H
!(!( & !)( !)( & !*(
!*( & !+( !+( & !)((
!)(($
*LL -OHR ,BSR
/LFB BNE =JDK
3SMI >YM]MU[I[Q]MZ 5VTM 3SMI @MSQMN
/LFB 9QFUFNSBSJUFR
0VTWIYQZVU 0PIY[
/QONSLJNF 9LTR 4( *EUBNSJW 22 *EUBNSBHF 22 ;FUOLTSJON
<FNSJNFL ,OMGOQSJR /QONSLJNF =OP <POS 9QOHQBM =BCLFSR
*EUBNSBHF 6TLSJ 9QO6FQJR /OQ -OHR9QFUFNSJD =JDK ,OLLBQ
GOQ -OHR
9QOHQBM 8QBL
<TRPFNRJON
+JO <POS /OQ -OHR =QJGFWJR9QO6FQJR /OQ ,BSR
+JO <POS /OQ ,BSR
9QOSJDBLL /OQ -OHR
+JO <POS /LFB ! =JDK
,OLLBQ VJSI 20; /OQ
-OHR
+JO <POS /LFB ! =JDK
,OLLBQ /OQ ,BSR !
4JSSFNR
1OMF /LFB ;FLJFG
0VTWIYQZVU 0PIY[
,LJDK ! 5FBQN
/LFB BNE =JDK
2Z[IJSQZP IU 2NNMK[Q]M 3SMI
>YM]MU[QVU >YVOYIT
3SMI IUL BQKR 0VTWIYQZVU 0PIY[
@BSDI ?JEFO)
/MUMNQ[Z VN CZQUO 3SMI IUL BQKR
>YM]MU[I[Q]MZ
@BSDI ?JEFO)
A[MWZ BV BIKRSM I 3SMI
6UNMZ[I[QVU
;FDOMMFNEBSJONR
,LFBN ! -FOEOQJYF .BQR)
&#'%%#9FS6FER .BQ ,LFBNRJNH<OLTSJON
4JLL /LFBR 7BSTQBLLX )
+F /LFB /QFF <PQBX
2MMFEJBSF /LFB ;FLJFG)
,BPRSBQ
Page 1 ofof 3Flea and Tick Control Products and Flea Medicines for Dogs and Cats - 1800PetMeds
5/3/2011http://www.1800petmeds.com/Flea+and+Tick-cat10.html
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 34 of 38
1-800-381-7179 Your Account Track Your Order Home 0 items
Welcome to DrsFosterSmith.com. Sign In #,0&. (0&+ ! -. )&21-.% '&.&
Search: Home > Dogs > Flea & Tick Control > Prescription Medications - Flea/Tick
FOCUS ON ARTICLES
SALE CENTER
NEW PRODUCTS
ONLINE ONLY
CLEARANCE PRODUCTS
GIFT CERTIFICATES
Flea & Tick Control
Control
Prescription Medications -Flea/Tick
Agility
Aids for Arthritic Dogs
Bark Control
Beds & Throws
Behavior & Calming Aids
Breeders
Cages, Crates & Kennels
Carriers
Cleanup
Clothing for Dogs
Collars & Harnesses
Cooling Products
Dental Care
DeShedding
Digestive Aids
Doors
Ear Care
Eco-Friendly
Eye Care
Feeders & Waterers
Fence Systems
Field Dog
First Aid
Flea & Tick Control
Food
Gates
Gifts for Pet Lovers
Grooming
Hair Pickup
Health Care
Heartwormers - Prescription
Hip & Joint Support
Housetraining
Incontinence
Indoor Control
Itchy Skin
Lawn Care
Leads & Leashes
Medications - Prescription
Monuments & Urns
Nail Care
Nametags
Odor Removal
Outdoor Supplies
Overweight Dogs
Paw Care
Puppy Care
Ramps & Stairs
Rawhide
Seat Covers
Senior Dog Care
Shed Control
Prescription Medications -Flea/TickKill fleas with an oral prescription medication option, likeComfortis. Or, control fleas and ticks, heartworm, and otherinternal parasites with prescription medication options likeRevolution and Sentinel.
Articles About Flea & Tick Control
VIDEO - How to Apply Topicals
VIDEO - How to Remove a Tick
Compare Flea & Tick Control Products
More...
4 results
Advantage Multi"Heartworm, FleaTopical for Dogs
by Bayer
As low as $69.99
Comfortis" ChewableTablets (Brand)
As low as $85.99
Revolution® (Brand)by Pfizer
As low as $36.99
Sentinel ® Tablets forDogs (Brand)by Novartis
As low as $11.60
4 results
Narrow Your Results:
Sort Results By:
Top Sellers(default)
Lowest $ to Highest $
Highest $ to Lowest $
Refine by Price:
$10 - $2525
$25 - $5050
$50 - $100
$100 - $150
Refine by Special:
FREE SHIPPING
QUICK LINKS:
SEARCH for Products or Articles:
#,0&. (0&+ ! -. )&21-.%
FREE Email Newsletters! Sign up for pet care tips & secret sale alerts:
#,0&. #+$(* "%%.&//
CUSTOMER SERVICE - HELP »
1-800-381-7179 »
SHIPPING RATES & INFO »
TRACK YOUR ORDER »
ABOUT US »
EMAIL SUBSCRIPTIONS »
NEW PUPPY EMAIL SERIES »
PUPPY CENTER »
KITTEN CENTER »
KIDS LEARNING CENTER »
POPULAR SEARCHES »
EASY BUY BUNDLES »
AWARDS & HONORS »
GIFT CERTIFICATES »
EMAIL REMINDER SERVICE »
SALE EMAIL ALERTS »
BUSINESS PARTNER PROGRAM »
CATERED PET® SERVICE »
PAWS FOR A CAUSE PROGRAM »
Visit our other websites:
DOG SUPPLIES
,() %!.(*',$+
)*(#-", "!,$&(*'$+
Page 1 ofof 2Dog Flea & Tick Control: Prescription Medication Solutions
5/3/2011http://www.drsfostersmith.com/dog-supplies/flea-tick/prescription-medications---flea-tick/ps/c/3307/6/21352
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 35 of 38
Browse All Products
Dental
Ear
Flea & Tick
Heartworm
Joint
Medications
Nutritional
Skin & Coat
Vet Supplies
Your cart is empty.
Home > Flea & Tick
Flea & Tick
Displaying products 1 - 73 of 73 resultsShow: 200 Sort: Default
Adams Flea & Tick Mist 16oz
Our Price: $9.97Adams Flea & Tick Mist 32oz
Our Price: $18.51
Advantage Cat Orange 0-9lbs - 4Dose Pack
Our Price: $44.42
Advantage Cat Orange 0-9lbs - 6Dose Pack
Our Price: $60.09
Advantage Cat Purple over 9lbs - 4Dose Pack
Our Price: $44.42
Advantage Cat Purple over 9lbs - 6Dose Pack
Our Price: $60.09
Advantage Dog Blue over 55lbs - 4Dose Pack
Our Price: $48.53
Advantage Dog Blue over 55lbs - 6Dose Pack
Our Price: $67.37
Advantage Dog Green 0-10lbs - 4Dose Pack
Our Price: $43.56
Advantage Dog Green 0-10lbs - 6Dose Pack
Advantage Dog Red 21-55lbs - 4 DosePack
Advantage Dog Red 21-55lbs - 6 DosePack
Home • Contact Us • Policies • Cart: 0 items ($0.00) • Checkout
Browse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet SuppliesBrowse All Products Dental Ear Flea & Tick Heartworm Joint Medications Nutritional Skin & Coat Vet Supplies
Page 1 ofof 6Vets Mall - Flea & Tick
5/3/2011http://www.vetsmall.com/fleacontrol.aspx
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 36 of 38
Our Price: $60.52 Our Price: $46.54 Our Price: $64.62
Advantage Dog Teal 11-20lbs - 4Dose Pack
Our Price: $44.41
Advantage Dog Teal 11-20lbs - 6 DosePack
Our Price: $61.66
Advantage Multi Cat Orange 5.1-9lbs -6 Dose Pack
Our Price: $70.71
Advantage Multi Cat Purple 9.1-18lbs- 6 Dose Pack
Our Price: $70.71
Advantage Multi Dog Blue 55.1-88lbs- 6 Dose Pack
Our Price: $78.23
Advantage Multi Dog Green 3-9lbs - 6Dose Pack
Our Price: $70.41
Advantage Multi Dog Red 20.1-55lbs -6 Dose Pack
Our Price: $76.40
Advantage Multi Dog Teal 9.1-20lbs -6 Dose Pack
Our Price: $71.83
Advantage Multi Kitten Turquoise 2-5lbs - 3 Dose Pack
Our Price: $31.90
Assurity 6 Dose
Our Price: $76.20
Assurity is a once-a-month topical fleacontrol for cats only
Assurity Single Dose
Our Price: $18.95
Capstar 11.4mg Blue 2-25lbs 6Tablets
Our Price: $25.88
Page 2 of 6Vets Mall - Flea & Tick
5/3/2011http://www.vetsmall.com/fleacontrol.aspx
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 37 of 38
Capstar 57mg Green 25-125lbs 6Tablets
Our Price: $28.13
Comfortis 10.1-20lbs Orange 6Tablets/ 6 Months
Our Price: $67.76
Comfortis 20.1-40lbs Teal 6 Tablets/ 6Months
Our Price: $70.25
Comfortis 40.1-60lbs Blue 6 Tablets/ 6Months
Our Price: $71.51
Comfortis 5-10lbs Pink 6 Tablets/ 6Months
Our Price: $66.50
Comfortis 60.1-120lbs Brown 6Tablets/ 6 Months
Our Price: $74.03
Frontline Plus Cat Teal (All Sizes) 3Dose Pack
Our Price: $29.86
.
Frontline Plus Cat Teal (All Sizes) 6Dose Pack
Our Price: $69.45Frontline Plus Dog Blue 23-44lbs- 3
Dose Pack
Our Price: $37.27
Frontline Plus Dog Blue 23-44lbs- 6Dose Pack
Our Price: $72.80
Frontline Plus Dog Orange under22lbs - 3 Dose Pack
Our Price: $36.40
Frontline Plus Dog Orange under22lbs - 6 Dose Pack
Our Price: $71.08
Frontline Plus Dog Purple 45-88lbs - 3Dose Pack
Our Price: $38.13
Frontline Plus Dog Purple 45-88lbs - 6Dose pack.
Our Price: $74.53Frontline Plus Dog Red 89-132lbs - 3
Dose pack
Our Price: $38.99
Page 3 of 6Vets Mall - Flea & Tick
5/3/2011http://www.vetsmall.com/fleacontrol.aspx
Case 1:11-cv-03047-AKH Document 1 Filed 05/04/11 Page 38 of 38
top related